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COMBINATION TREATMENT APPROACH FOR TRAUMATIC SPINAL CORD 
INJURY 
 
 
 
Spinal cord injury (SCI) is devastating and debilitating, and currently no 
effective treatments exist.  Approximately, 12,000 new cases of SCI occur 
annually in the United States alone.  The central nervous system has very low 
repair capability after injury, due to the toxic environment in the injured tissue.  
After spinal cord trauma, ruptured blood vessels cause neighboring cells and 
tissues to be deprived of oxygen and nutrients, and result in the accumulation of 
carbon dioxide and waste.  New blood vessels form spontaneously after SCI, but 
then retract as the injured tissue forms a cavity.  Thus, the newly formed 
vasculature likely retracts because it lacks a structural support matrix to extend 
across the lesion.  Currently, in the field of spinal cord injury, combinational 
treatment approaches appear to hold the greatest therapeutic potential.  
Therefore, the aim of these studies was to transplant a novel, non-immunogenic, 
bioengineered hydrogel, into the injured spinal cord to serve as both a structural 
scaffold (for blood vessels, axons, and astrocytic processes), as well as a 
functional matrix with a time-controlled release of growth factors (Vascular 
endothelial growth factor, VEGF; Glial cell line-derived neurotrophic factor, 
GDNF).  The benefit of this hydrogel is that it remains liquid at cooler 
temperatures, gels to conform to the space surrounding it at body temperature, 
and was designed to have a similar tensile strength as spinal cord tissue.  This is 
vii 
advantageous due to the non-uniformity of lesion cavities following contusive 
spinal cord injury.  Hydrogel alone and combinational treatment groups 
significantly improved several measures of functional recovery and showed 
modest histological improvements, yet did not provoke any increased sensitivity 
to a thermal stimulus.  Collectively, these findings suggest that with further 
investigation, hydrogel along with a combination of growth factors might be a 
useful therapeutic approach for repairing the injured spinal cord. 
 
 
Ellen A. G. Chernoff, Ph.D. – Chair 
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INTRODUCTION 
 
History of Spinal Cord Injury 
 
Spinal cord injury (SCI) results in a lifetime of devastating disabilities and 
yet, currently no effective treatments exist.  The first documented cases of SCI 
were written in approximately 3,000 B.C.E., with details contained within the 
Edwin Smith papyrus.  This papyrus was translated by Dr. James Henry 
Breasted in 1922 (partial translations) and in its entirety in 1930 (Hughes 1988).  
This papyrus is noteworthy on several levels, not only to be the first document 
to report on SCI, and to be considered as possibly the first medical papyrus in 
existence, but also because it is considered to be the first written piece 
designated as a scientific document (Hughes 1988).  It is speculated that the 
Egyptian physician and architect, Imhotep, detailed the first cases of SCI, either 
from battle wounds or construction site injuries (Hughes 1988). 
Approximately 5,000 years later, neurosurgeons and 
neurotraumatologists are still challenged to find a treatment for the debilitating, 
chronic neurological deficits resulting from SCI.  In the nineteenth century, 
Santiago Ramon y Cajal encouraged future neuroscientists to try to change the 
‘irreversibility’ of the central nervous system (CNS), which he described as 
forever fixed after development and differentiation (Schwab and Bartholdi, 
1996).  Attempting to repair the injured CNS is demanding and perplexing, yet, 
neuroscientists, neurosurgeons, and neurotraumatologists of today (Figure 1) 
have nonetheless accepted this challenge and are forging ahead with potential 
therapeutic approaches for all those suffering from this devastating condition. 
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Figure 1. History of Spinal Cord Injury.  Following Imhotep’s initial documented 
cases of spinal cord injury, neuroscientists and neurotraumatologists have been 
working for over 5,000 years to find a cure for this devastating and debilitating 
condition.  This is not an exhaustive list of SCI researchers.  It is noteworthy that a 
majority of the SCI scientists (listed below Drs. Richard and Mary Bunge) are first, 
second, or third generation SCI scientists trained by Drs. Richard and Mary Bunge. 
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Spinal Cord Injury Background 
This dissertation document will present an overview of spinal cord injury 
including the major causes; the resulting tissue destruction; inhibitory 
components to nervous system repair; a background of the literature, primarily 
focusing upon vascular endothelial growth factor (VEGF), glial cell line-derived 
neurotrophic factor (GDNF), bioengineered tissues, and combinational 
therapeutic approaches, as rationale for our designed combinational treatment 
approach (including VEGF and GDNF); the endogenous repair mechanisms; 
data from conducted research studies; limitations of the study; VEGF and 
GDNF for other neurodegenerative diseases; and future directions for use of 
bioengineered tissues for therapeutic approaches for SCI. 
Motor vehicle accidents, falls, and sports injuries are the primary causes 
of SCI cases worldwide (Singh et al., 2014).  SCI involves an initial mechanical 
insult that tears, shears, punctures, or compresses the spinal cord, resulting in a 
breakdown of the blood-spinal cord barrier (Noble and Wrathall, 1987, 1988, 
1989; Popovich et al., 1996).  A secondary wave of injury ensues, comprised of 
vascular hemorrhage (Oudega 2012), ischemia (Tator and Fehlings, 1991), 
edema, excitotoxicity, and chronic inflammation (Mautes et al., 2000; Oudega 
2013; Blomster et al., 2013).   The resulting toxic milieu leads to neuronal, glial, 
and vascular cell death (all components of the neurovascular unit), axonal 
degeneration, loss of gray and white matter tissue (Tator and Koyanagi, 1997), 
and glial scar formation (Hagg and Oudega, 2006).  On a systems-level this can 
lead to motor and sensory loss of function.  On a global scale, this often leads to 
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paralysis, spinal shock, autonomic dysreflexia, loss of bowel and bladder 
function (depending upon level and severity of injury), loss of sexual function, 
pressure ulcers, chronic inflammation, and chronic pain. 
Despite centuries of medicine and science suggesting that CNS neural 
networks were irrevocably ‘fixed’ and unable to be modulated or regenerated 
after degeneration or injury, the last half century has experienced tremendous 
strides in neural regeneration progress.  Recent literature in the field of 
neurotrauma suggests that combinational treatment approaches appear to hold 
the greatest therapeutic promise (Xu et al., 1995; Guest et al., 1997; Sayer et 
al., 2002; Fouad et al., 2005; Bunge MB, 2008; Lutton et al., 2011; Lu et al., 
2012; Deng et al., 2013; Ansorena et al., 2013).  These studies will be 
described in more detail in later chapters. 
Astonishingly, despite the toxic environment at lesion epicenter after SCI, 
an endogenous vascular response occurs, which peaks between 7-14 days post-
injury, and regresses coincident with the onset of cystic cavitation, in both rats 
and higher primates (Loy et al., 2002; Casella et al., 2002; Benton et al., 2008a; 
Fassbender et al., 2011).  We hypothesized that the angiogenic vasculature 
regresses due to a loss of structural support, with the onset of cystic cavitation.  
Therefore, the overall goal of this dissertation research was to provide a 
structural scaffold for vascular reorganization, axonal regrowth, and tissue repair 
following contusive SCI, by employing our novel bioengineered hydrogel. 
In one of the earliest studies utilizing biomaterials for SCI repair 
(Marchand and Woerly,1990) although an immune response was provoked, 
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beneficial host astrocytic and axonal regrowth into the collagen matrix occurred.  
A few years later, this group (Marchand et al., 1993) reported on the optimization 
of their biomaterial by cross-linking their collagen bioimplant with carbodiimide, 
which resulted in a positive modification of the glial scar, improved biomechanical 
properties, and enhanced axonal growth into the implant.  By 2001, this group of 
colleagues tested their novel bioengineered hydrogel (Neurogel™) on a chronic 
compressive SCI model (subdural inflated balloon), transplanting their 
Neurogel™ at 3-months post SCI (Woerly et al., 2001a).  Significant 
improvements were observed in BBB locomotion (enhanced by an enriched 
housing environment), accompanied by axonal growth, angiogenic vascular 
growth, and astrocytic process growth into the hydrogel implant (Neurogel™), 
including myelinated axons and functional (dendro-dendritic) connections 
(Woerly et al., 2001a).  This study greatly enhanced the use of bioengineered 
tissues for SCI, particularly because of the beneficial motor effects and 
histological outcomes on a chronic injury model.  Since there are over 250,000 
Americans suffering from SCI, and an even greater number globally, chronic SCI 
treatments are even more substantial than treatments that must be administered 
acutely.  It is difficult to administer therapeutics to injured patients within several 
hours after injury (acutely), partially because some patients do not make it to the 
medical center in under a few hours after injury.  For example, people injured in 
the battlefield or in an earthquake may not be transported to the medical facility 
or even located (in the aftermath of an earthquake) for a number of hours after 
injury.  Additionally, once suspected SCI patients arrive at the hospital, their 
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vertebral columns must be stabilized and then scans are performed to assess the 
presence of spinal cord injury, which again occupies more time post injury.  
Therefore, therapies that can be administered subacutely or in the chronic 
phases after SCI will have the widest impact for SCI patients.    
In addition to promoting axonal, astrocytic, and vascular ingrowth into 
transplanted biomaterials for tissue repair, various groups began to realize the 
importance of longitudinally directed growth of regenerating axons.  In 2006, 
Prang et al., delivered an alginate-based anisotropic capillary hydrogel into a rat 
model of cervical dorsal column transection, which promoted directional axonal 
regrowth into the transplanted hydrogel without provoking an immune response.  
Some SCI studies have observed axonal regrowth into the lesion area, without 
directed growth, thus resulting in random axonal growth within the lesion.  The 
ultimate goal of axonal regrowth into the lesion epicenter is growth through-and-
beyond the distal end of the lesion and functional reconnections of these axons 
with their target neurons.  This is necessary in order to create a full connection of 
neuronal activity from the brain down through the spinal cord, to the neurons that 
connect to the muscles in our limbs and our internal organs, for movement and to 
sustain life (heartbeat, respiration, digestion, bladder function).    
Aside from serving as a structural scaffold, biomaterials also serve as 
functional reservoirs for embedded trophic factors and transplanted cells.  
Through the use of a poly(lactic-co-glycolic acid) outer hydrogel membrane and a 
poly(ethylene glycol)/poly-l-lysine hydrobromide hydrogel inner layer, embedded 
with endothelial and neural progenitor cells, Rauch et al. (2009) observed two-to-
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four-fold increases in the number of intralesional functional vasculature, and the 
formation of a blood-spinal cord barrier.  Intralesional vasculature is crucial for 
delivering oxygen and nutrients to the tissues and for the removal of cellular 
waste.  Moreover, an intact blood-spinal cord barrier is crucial for minimizing the 
inflammatory mediators that extravasate from the blood vessels and result in a 
wave of secondary tissue degeneration and chronic inflammation.  Therefore, 
this study nicely demonstrates the potential of bioengineered tissues for 
combinational treatment approaches. 
Piantino and colleagues (2006) delivered a photoactivated hydrogel in 
combination with neurotrophin-3, in a thoracic transection model of SCI.  
Significant axonal growth of the corticospinal and raphespinal tracts was 
observed.  The authors note that the promoted outgrowth from two descending 
corticospinal tracts may have primarily resulted from sprouting from undamaged 
ventral corticospinal tract.  Many studies have shown that regrowth of damaged 
descending tracts, such as the corticospinal and raphespinal tracts, is very 
challenging and greatly limited.  Regrowth is much more probable with the 
descending propriospinal tract after SCI (Deng et al., 2013, 2014, 2015).  
Collectively, these studies employing biomaterials give us insight into the 
usefulness of bioengineered tissues for combinational treatment approaches for 
repairing the injured spinal cord and central nervous system. 
The Belgian Anatomist, Andreas Vesalius, reported in his 1543 
publication (De humani corporis fabrica, On the fabric of the human body, 1543) 
on the overlap of the nervous and vascular systems (Carmeliet and Tessier-
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Lavigne, 2005). The intertwining of these two systems led to the hypothesis that 
a similar trophic factor might influence the development of both systems.  Dr. 
Peter Carmeliet and colleagues have been vital in linking the nervous and 
vascular systems (Carmeliet and Storkebaum, 2002; Storkebaum et al., 2004a; 
Storkebaum and Carmeliet, 2004b; Zacchigna et al., 2008; Ruiz de Almodovar 
et al., 2009; Carmeliet and Ruiz de Almodovar, 2013).  The neurovascular 
evolution of VEGF (vascular endothelial growth factor) and its influence on the 
nervous system was nicely summarized by Zacchigna, Carmeliet and 
colleagues (2008).  This publication displayed the importance of the human 
VEGF homologue in C. elegans (Caenorhabditis elegans) and Drosophila 
melanogaster, which lack blood vessels or have very few, respectively.  
Additionally, Popovici et al. (2002) described receptors on neurons in C. 
elegans with structural similarity to the human VEGF receptors (VEGFRs), 
which can activate human VEGFRs (Zacchigna et al., 2008).  This seminal 
paper describes the role of VEGF beyond its canonical role in the vascular 
system (Zacchigna et al., 2008), and details the pleiotropic influence of VEGF 
on the nervous, vascular, glial, and immune systems. 
In addition to the publications from Carmeliet and colleagues describing 
the pleiotropic influence of VEGF, and the VEGF homologs in C. elegans (which 
lack blood vessels) and Drosophila (which have very few blood vessels), 
several other factors prompted us to employ VEGF embedded within 
bioengineered hydrogel for treatment of traumatic SCI.  First, publications 
showing the angiogenic vasculature regresses following SCI, at the onset of 
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cavitation (Loy et al., 2002; Casella et al., 2002; Benton et al., 2008a; 
Fassbender et al., 2011).  Second, deletions within the VEGF promoter region 
cause a neurodegenerative phenotype in mice, similar to Amyotrophic Lateral 
Sclerosis (ALS), showing VEGF is important for maintenance of motor function 
(Oosthuyse et al., 2001).  Third, Lambrechts et al. (2003) showed motoneuron 
protection by VEGF administration in an ALS mouse model.  Additionally, this 
study also showed that VEGF serum levels in European patients correlated with 
ALS susceptibility, with lower circulating VEGF levels correlating with higher risk 
of sporadic ALS.  Next, VEGF delivered via a retroviral vector delayed disease 
onset, promoted neuroprotection, and prolonged survival of animals with an 
ALS phenotype (Azzouz et al., 2004).  Similarly, VEGF delivered 
intracerebroventricularly prolonged the survival period, delayed the disease 
onset, and spared motor neurons in an ALS model (Storkebaum et al., 2005).  
Moreover, intact vasculature is crucial for delivering oxygen and nutrients to the 
tissues and for removing toxic wastes.  Therefore, we hypothesized that 
delivering VEGF to the lesion epicenter via a bioengineered hydrogel might 
positively influence the endogenous angiogenic response while promoting 
neuron survival and growth, Schwann cell migration and survival, and 
influencing microglia and astrocytes (Storkebaum et al., 2004a).   
In 2007, Tufro et al., showed an interaction of VEGF and GDNF (glial cell 
line-derived neurotrophic factor) at the RET proto-oncogene receptor, with a 
possible additive effect on cell outgrowth.  Moreover, VEGF and GDNF robustly 
influenced animal survival, delayed disease onset, and maintained motor 
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function in an ALS neurodegenerative disease model (Krakora et al., 2013).  
VEGF and GDNF also had an additive effect on neuron survival and increased 
the axon fiber density compared to control animals or animals receiving VEGF 
or GDNF alone, in a Parkinson’s disease model (Herran et al., 2013). 
Spinal cord injury literature has shown GDNF promotion of 
neuroprotection (Arce et al., 1998; Soler et al., 1999; Nicole et al., 2001), axonal 
growth (Blesch and Tuszynski, 2001; Dolbeare and Houle, 2003), reduction of 
astrogliosis (Iannotti et al., 2003; Deng et al., 2011a; Ansorena et al., 2013), 
increased myelination (Zhang et al., 2009; Deng et al., 2013), increased 
intralesional vasculature (Zhang et al., 2009; Ansorena et al., 2013), and 
improved functional recovery (Cheng et al., 2002; Kao et al., 2008; Deng et al., 
2013; Ansorena et al., 2013).  Additionally, in a Parkinson’s disease model, 
Iravani et al. (2012) observed neuroprotection following GDNF administration.  
In a combinational treatment approach, neural stem cells secreting GDNF 
conferred striatal neuroprotection in a Huntington’s disease model (Pineda et 
al., 2007).  In another Huntington’s disease model study, GDNF delivered via an 
adeno-associated viral vector into the striatum, provided neuroprotection to both 
nitric oxide synthase striatal interneurons as well as parvalbumin striatal 
interneurons (Kells et al., 2004).  Following SCI, Zhang et al. (2009) showed 
that GDNF administration increased the number of myelinated axons and the 
number of blood vessels.  In an SCI combinational therapeutic strategy, GDNF 
released from a Schwann cell-seeded guidance channel, with Schwann cells 
overexpressing GDNF, positively modulated the inhibitory astrocytic glial scar, 
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created a more permissive environment for propriospinal axonal regrowth 
through-and-beyond the distal end of the lesion, conducted electrical signals 
through the lesion gap, and improved functional recovery (Deng et al., 2013).  
Collectively, these studies highlight the importance of combinational treatment 
approaches for traumatic spinal cord injury, and encouraged us to employ the 
combination of VEGF and GDNF, slowly released from a novel bioengineered 
hydrogel, for the treatment of traumatic spinal cord injury. 
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PART I: Vascular Endothelial Growth Factor and Spinal Cord Injury 
VEGF Background 
Vascular endothelial growth factor (VEGF) is an important signaling 
molecule intimately associated with angiogenesis (Folkman et al. 1971; 
Carmeliet et al., 1996), axonal guidance (Ruiz de Almodovar et al., 2011; 
Carmeliet & Ruiz de Almodovar et al., 2013; Zachary et al., 2005), 
neuroprotection (Storkebaum et al., 2004a; Facchiano et al., 2002; Widenfalk et 
al., 2003; Zacchigna et al., 2008), Schwann cell survival and migration, and 
proliferation of astrocytes, microglia, and neural stem cells (Storkebaum et al., 
2004a).  Thus, making this pro-angiogenic factor a therapeutic target for 
promoting spinal cord revascularization, neuroprotection, cell proliferation, tissue 
regeneration, and ultimately improved functional recovery.  This introduction 
therefore, focuses on the background of VEGF as an angiogenic trophic factor 
and its more recently discovered pleiotropic role in the nervous systems, as well 
as its potential influence for tissue repair following traumatic spinal cord injury. 
Discovery of VEGF and its Receptors 
VEGF is well known for its influence on vasculature and has been widely 
characterized in cardiovascular and cancer research and medicine.  In more 
recent decades, VEGF has also been recognized for its role in embryonic 
development (Carmeliet et al., 1996), its pleiotropic effects (Storkebaum et al., 
2004a; Rosenstein and Krum, 2004; Carmeliet et al., 2013) on neurons and glia, 
and its therapeutic potential to prevent neurodegeneration (Herran et al., 2013; 
Azzouz et al., 2004; Emerich et al., 2010; Storkebaum and Carmeliet, 2004b). 
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Dr. Judah Folkman and colleagues extensively studied endothelial cell 
activation and angiogenesis, intricately associated with tumor growth and 
survival, characterizing the trophic factor as Tumor-Angiogenesis Factor (TAF; 
Folkman et al., 1971) with seminal papers during the 1970s.  Previous studies 
displayed the factor’s potential to act at a distance, after diffusing across a 
membrane (Greenblatt et al., 1992; Ehrman et al., 1992).  Vascular Endothelial 
Growth Factor (VEGF), a gene family comprised of five major proteins along with 
receptors and co-receptors, was originally termed Vascular Permeability Factor 
(VPF) in 1983 (Senger et al., 1983) by Drs. Sanger and Dvorak.  In 1989, this 
vascular trophic factor, which resulted in extensive endothelial cell outgrowth and 
angiogenesis, was termed VEGF by Drs. Ferrara and Henzel at Genentech 
(Ferrara et al., 1989).  The neurovascular evolution of VEGF and its influence on 
the nervous system was summarized by Zacchigna, Carmeliet and colleagues 
(2008), displaying the importance of the human VEGF homologue in C. elegans 
(Caenorhabditis elegans) and Drosophila melanogaster, which lack blood 
vessels or have very few, respectively.  Additionally, Popovici et al. (2002) 
described receptors on C. elegans neurons with structural similarity to the human 
VEGF receptors (VEGFRs), which can activate human VEGFRs (Zacchigna et 
al., 2008).  Dr. Peter Carmeliet has been instrumental in expanding and detailing 
the Belgian Anatomist, Andreas Vesalius’ 1543 observations about the overlap of 
the nervous and vascular systems (De humani corporis fabrica, On the fabric of 
the human body, 1543), thus, proving the pleiotropic influence of VEGF on the 
nervous, vascular, and immune systems (Carmeliet and Tessier-Lavigne, 2005). 
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VEGF Isoforms and Co-receptors 
The VEGF sub-family of growth factors belongs to the platelet-derived 
growth factor (PDGF) family, and is comprised of isoforms VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E, and PGF (placental growth factor), summarized by 
Grünewald et al. (2010).  Together, these trophic factors are responsible for 
embryonic vasculogenesis, the formation of new blood vessels, as well as the 
development of blood vessels from existing blood vessels (angiogenesis).  
Human VEGF exists as a homodimer (~45 kDa under non-reducing conditions, 
and ~23 kDa under reducing conditions; Ferrara et al., 1989) and is synonymous 
with VEGF-A.  Alternative splicing of the human VEGF-A gene (cytogenetic 
location 6p12, 9 exons; www.ncbi.nlm.nih.gov/gene/7422) generates five distinct 
VEGF-A monomers including VEGF121, VEGF145, VEGF165, VEGF189, and 
VEGF206, designated by the number of amino acids in the sequence.  VEGF-B is 
located on chromosome 11 (cytogenetic location 11q13, 7 exons; 
www.ncbi.nlm.nih.gov/gene/7423).  VEGF-C is located on chromosome 4 
(cytogenetic location 4q34.3, 7 exons; www.ncbi.nlm.nih.gov/gene/7424).  VEGF-
D is located on the X chromosome (cytogenetic location Xp22.31, 7 exons; 
www.ncbi.nlm.nih.gov/gene/2277).  The non-human VEGF-E, encoded by the 
parapoxvirus Orf virus (OV; Meyer et al., 1999) is located on chromosome 4 
(cytogenetic location 4q32, 8 exons; Wise et al., 2012).  PGF is located on 
chromosome 14 (cytogenetic location 14q24.3, 7 exons; 
www.ncbi.nlm.nih.gov/gene/56034).  VEGF-E binds selectively to VEGFR-2, and 
has been shown to promote lesion angiogenesis in response to the viral infection 
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by the parapoxvirus Orf virus (OV; Meyer et al., 1999), and regulation of 
keratinocytes for wound re-epithelialization in response to the purified VEGF-E 
protein15 that this virus encodes, thus making it a potentially good candidate for 
wound healing and repair.  Moreover, since VEGF-E binds only to VEGFR-2 and 
not to VEGFR-1, it does not result in vascular permeability or tissue 
inflammation, like VEGF-A (Wise et al., 2012).  Thus, purified VEGF-E might 
have potential in tissue repair beyond just would healing. 
Two tyrosine kinase receptors, VEGF Receptor 1 (VEGFR-1, fms-like 
tyrosine kinase 1/Flt-1; www.ncbi.nlm.nih.gov/gene/5228) and VEGF Receptor 2 
(VEGFR-2, fetal liver kinase 1/Flk-1, kinase insert domain receptor/KDR) were 
identified in 1992 (de Vries et al.; Terman et al.).  Neuropilin (NP1 and NP-2) co-
receptors bind specifically to VEGF isoform 165 (VEGF165 in humans, VEGF164 in 
rats).  The human VEGFR-1 gene is located on chromosome 13 (cytogenetic 
location 13q12, 32 exons; www.ncbi.nlm.nih.gov/gene/2321) and VEGFR-2 gene 
is located on chromosome 4 (cytogenetic location 4q11-q12, 30 exons; 
www.ncbi.nlm.nih.gov/gene/3791).  VEGF Receptor 3 (VEGFR-3, fms-like 
tyrosine kinase 4/Flt-4; www.ncbi.nlm.nih.gov/gene/2324) was independently 
characterized in 1992 by Galland et al. (1992) and Pajusola and colleagues 
(1992).  The cytogenetic locations for all VEGF proteins and receptors are 
summarized in Table 1.  All three VEGF Receptors are type V receptor tyrosine 
kinases (RTK’s), consisting of an extracellular region (7 immunoglobulin-like 
domains), a single transmembrane domain, a juxtamembrane component, and 
an intracellular protein-tyrosine kinase segment with a variable (70-100 amino 
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acids) kinase insert and a carboxyterminal tail (Roskoski Jr. et al., 2007).  The 
main pathway promoting angiogenesis is the interaction of VEGF-A (VEGF) and 
its VEGFR-2 receptor; particularly, the phosphorylation of the VEGFR-2 Tyrosine 
residue 1175, which binds to the SH2-domain of  Phospholipase-Cɣ (PLCɣ), 
upstream of the PKC mitogen-activated protein kinase/extracellular signal-related 
kinases (MAPK/ERK) pathway.  Ji et al. (1997) showed that PLCɣ knockout mice 
were embryonic lethal at approximately day E9.  VEGFR-1 knockout mice were 
shown to be embryonic lethal at E8.5, resulting from disorganized vasculature 
and endothelial cell-overgrowth (Hiratsuka et al. 2005); this study also displays 
the importance of the transmembrane domain of VEGFR-1, which localizes 
VEGF for signaling during embryogenesis, and negatively regulates 
angiogenesis.   Takashima et al. (2002) observed embryonic lethality (E8.5) 
in NRP-1 and NRP-2 knockout animals, due to lack of blood vessel formation.  In 
1996, both Carmeliet et al. and Ferrara et al. discovered the dose-dependent 
embryonic lethality of homozygous VEGF-/- knockout animals (E10.5 and E11-12, 
respectively) and heterozygous VEGF+/- animals (approximately E12.5), due to 
lack of formation of functional vasculature and significant cell apoptosis.    
Furthermore, Ferrara et al. (1996) detailed the significantly diminished capacity 
for tumorigenesis of VEGF-/- knockout embryonic stem cells; thus, underscoring 
VEGF’s role in tumor formation and the critical role of angiogenesis in tumor 
growth.  While VEGF, VEGFR-1 (Flt-1), and VEGFR-2 (Flk-1) are all essential 
components of embryonic development, these studies (Carmeliet et al. 1996 and 
Ferrara et al. 1996) highlight VEGF as the most vital factor, due to VEGF+/- 
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embryonic lethality (Ferrara et al. 1996).  Collectively, these studies display the 
importance of VEGF, its receptors and downstream signaling pathways for 
angiogenesis, embryonic development, and tumorigensis.  VEGF ligand isoforms 
and receptor interactions are summarized in Figure 2. 
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Figure 2.  Intracellular Signaling of VEGF.  VEGF-A binds to VEGFR-1 
(VEGF Receptor 1), VEGFR-2 (VEGF Receptor 2), NRP-1 (Neuropilin-1 
receptor), and NRP-2 (Neuropilin-2 receptor).  VEGF-B and PGF (Placental 
Growth Factor) bind to VEGFR-1.  VEGF-C and VEGF-D bind to VEGFR-2 and 
VEGFR-3 (VEGF Receptor 3).  Downstream signaling leads to angiogenesis, 
vasculogenesis, lymphanogiogenesis, vascular permeability, cell survival 
(inhibition of apoptosis), migration, proliferation, and mobilization of progenitors.  
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Figure 2 Abbreviations: VEGF-A (Vascular Endothelial Growth Factor A), 
VEGF-B (Vascular Endothelial Growth Factor B), VEGF-C (Vascular Endothelial 
Growth Factor C), VEGF-D (Vascular Endothelial Growth Factor D), PGF 
(Placental Growth Factor), VEGFR-1 (Vascular Endothelial Growth Factor 
Receptor 1), VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2), 
VEGFR-3 (Vascular Endothelial Growth Factor Receptor 3), NRP-1 (Neuropilin-1 
Receptor), NRP-2 (Neuropilin-2 Receptor), PI3K (Phosphatidylinositol-4,5-
bisphosphate 3-kinase), Rac (Ras-related C3 botulinum toxin substrate 1), Ras 
(Rat sarcomas, small GTPase), RhoA (Ras homolog gene family, member A), 
FAK (Focal Adhesion Kinase), PTEN (Phosphatase and tensin homolog), 
Paxillin, Survivin, Caspase-9, Akt (Protein kinase B), FOX (Forkhead box), PLC-γ 
(Phospholipase C, gamma), PKC (Protein kinase C), BAD (Bcl-2-associated 
death promoter), Raf (Rapidly Accelerated Fibrosarcoma), mTOR (mechanistic 
target of rapamycin), ROC (Ras of Complex protein), NO (Nitric oxide), eNOS 
(endothelial Nitric Oxide Synthase), AA (Arachidonic acid), cPLA2 (calcium-
dependent Phospholipase A2), ERK (Extracellular signal Regulated Kinases), 
MEK (Mitogen-activated protein kinase kinase). 
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Protein Cytogenetic location Reference 
VEGF-A   cytogenetic location 6p12,  9 exons www.ncbi.nlm.nih.gov/gene/7422 
VEGF-B   cytogenetic location 11q13,  7 exons www.ncbi.nlm.nih.gov/gene/7423 
VEGF-C   cytogenetic location 4q34.3,  7 exons www.ncbi.nlm.nih.gov/gene/7424 
VEGF-D   cytogenetic location Xp22.31,  7 exons www.ncbi.nlm.nih.gov/gene/2277 
VEGF-E    cytogenetic location 4q32, 8 exons, Orf virus  Wise et al., 2012 
PGF   cytogenetic location 14q24.3,  7 exons http://www.ncbi.nlm.nih.gov/gene/5228 
VEGF 
Receptor 1  
cytogenetic location 13q12, 
 33 exons http://www.ncbi.nlm.nih.gov/gene/2321 
VEGF 
Receptor 2  
cytogenetic location 4q11-
q12, 
 30 exons 
www.ncbi.nlm.nih.gov/gene/3791 
VEGF 
Receptor 3  
cytogenetic location 5q35.3, 
 34 exons www.ncbi.nlm.nih.gov/gene/2324 
 
 
Table 1.  VEGF Ligand and Receptor Cytogenetic Locations. 
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Table 2.  VEGF Ligand and Receptor Expression Patterns. 
22 
Localization of VEGF and its Receptors 
VEGF-A mRNA is widely expressed throughout the body, with the highest 
expression in the lungs, heart, adrenal glands, and kidneys, and lower 
expression in the liver, spleen, and gastric mucosa (Roskoski et al., 2007).  
VEGF-A is also a major target for anti-tumor therapies, as VEGF-A is expressed 
by the following human tumors: colorectal, breast, non-small cell lung, and 
prostate (Roskoski et al., 2007).  VEGF-B is highly expressed in the heart, brain, 
testes, and kidney, with lower expression in spleen, lung, and liver (Roskoski et 
al., 2007).  VEGF-C is expressed in the heart, intestine, ovaries, and the placenta 
(HPRD: 03317; ID: 01889).  VEGF-D is expressed in the colon, heart, kidney, 
liver, lung, ovaries, pancreas, prostate, skeletal muscles, small intestine, spleen 
and testis (HPRD: 02102, ID: 03237).  PGF is expressed in the dentine matrix, 
endometrium, eyes, natural killer cells, placenta, serum, trophoblasts, umbilical 
vein endothelial cells, and vascular endothelium (HPRD: 03076, ID: 02102). 
VEGFR-1 is expressed in blood vessels, bone marrow, colon, endometrium, 
epididymis, fetus, leydig cells, monocytes, ovaries, pancreas, placenta, prostate, 
seminiferous tubule, Sertoli cells, testis, and urothelium (HPRD: 01297, ID: 
10529).  VEGFR-2 is expressed in the bone marrow, heart, hematopoietic stem 
cells, mammary gland, neurons, placenta, testis, and urothelium (HPRD: 01867, 
ID: 03076).  Neurons more widely express VEGFR-2 while VEGFR-1 is more 
abundant on glial cells (Zacchigna et al., 2008).  As VEGF-A165 is the most 
abundant and most biologically active (pro-angiogenic) isoform of VEGF 
molecules, the remainder of this review will primarily focus on VEGF-A165 
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(VEGF165) and its therapeutic application for spinal cord injury repair.  Tissue 
expression of VEGF and its receptors is summarized in Table 2. 
Synergistic Activation of VEGF Receptors 
In 2001, Carmeliet and colleagues observed synergistic activation of the 
VEGFR-1 receptor by VEGF and PGF to promote angiogenesis (Carmeliet et al., 
2001, adapted illustration Figure 3).  During embryogenesis, VEGFR-1 is 
primarily a soluble receptor, which inhibits angiogenesis by binding VEGF and 
thus preventing VEGF from binding to the cell-surface VEGFR-2, which promotes 
angiogenesis (Shibuya 2006).  PGF binds to both the membrane-bound VEGFR-
1 and the soluble inhibitory form of VEGFR-1.  Thus, during embryogenesis, PGF 
can bind to the soluble form of VEGFR-1 and allow VEGF to bind to the 
membrane-bound VEGFR-2 to promote angiogenesis.  In contrast, under 
pathological conditions VEGFR-1 is primarily membrane-bound on endothelial 
cells, and PGF is upregulated.  Thus, PGF can activate VEGFR-1 while VEGF 
binds VEGFR-2, both promoting angiogenesis.  Carmeliet et al. (2001) described 
a synergistic effect on the promotion of angiogenesis when PGF activated the 
membrane-bound VEGFR-1 while VEGF activated the membrane-bound 
VEGFR-2.  While PGF and VEGF both activate VEGFR-1, PGF results in the 
phosphorylation of tyrosine residue 1309 while VEGF165 promotes the 
phosphorylation of tyrosine 1213 (Autiero et al., 2003). 
 
 
 
24 
 
 
 
 
Figure 3.  Pathological Switch Promoting Angiogenesis.  Synergistic 
activation of VEGFR-1 (soluble and membrane-bound forms) under 
embryonic conditions, by VEGF and PGF, primarily the soluble form of 
VEGFR-1, which negatively regulates angiogenesis.  Under pathological 
conditions VEGF primarily binds to VEGFR-2 while PGF primarily binds to 
membrane-bound VEGFR-1, and both VEGF receptors promote 
angiogenesis after a pathological insult. 
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VEGF levels and VEGF Receptor Expression after SCI 
Bartholdi et al. (1997) and Herrera et al. (2009) observed reduced VEGF 
levels at injury epicenter at 1 day post SCI with diminished VEGF levels as far as 
1 month post SCI.  Additionally, Ritz et al. (2010) reported reduced levels of 
VEGF, Angiopoietin-1 (Ang-1), PDGF-BB, and PGF, and increased expression of 
the angiogenic factor (HGF, hepatocyte growth factor).  VEGF receptors Flt-1 
and Flk-1 have been shown to be constitutively expressed by vascular 
endothelial cells, neurons, and some astrocytes in the spinal cord (Choi et al., 
2007).  Following SCI, VEGFR1 (Flt-1), VEGFR2 (Flk-1) and neuropilin-1 
receptors have been shown to be upregulated in reactive astrocytes and 
microglia/macrophages following contusive SCI (Choi et al., 2007; Skold et al., 
2000).  This receptor expression peaked between 7 and 14 days following injury 
and remained relatively high even at 14 days and beyond (Choi et al., 2007).  
Taken together, this suggests that VEGF and its two tyrosine kinase receptors 
play a role in inflammation and the astrocytic response following contusive spinal 
cord injury.  However, Skold et al. (2000) in vitro study suggests that upregulation 
of VEGF, its receptors and co-receptors in astrocytes may occur in the absence 
of inflammatory cells, with prostaglandins being upstream of VEGF. 
Studies Employing VEGF for SCI Repair 
VEGF has become a therapeutic target for spinal cord injury repair 
primarily over the past two decades.  Fassbender et al. (2011) nicely reviews the 
literature on microvascular dysfunction following SCI, and details the importance 
of putative therapeutic approaches targeting the microvasculature.  VEGF routes 
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of administration vary from: exogenously applied (intrathecal and intraspinal 
injections, osmotic mini pumps; Widenfalk et al., 2003; Benton and Whittemore 
2003; Herrera et al., 2009); engineered transcription factor activation of 
endogenous VEGF expression (Liu et al., 2010); overexpression via cells (Kim et 
al., 2009), viral vectors (Facchiano et al., 2002; Figley et al., 2014), or in 
response to other neurotrophic factor administration (GDNF; Kao et al., 2008), or 
as a result of shockwave therapy (Yamaya et al., 2014), amongst others.  VEGF 
has been shown to be neuroprotective (Facchiano et al., 2002); promote 
angiogenesis (Facchiano et al., 2002; Figley et al., 2014; des Rieux et al., 2014) 
and oligodendrogenesis; improve myelin integrity (Sundberg et al., 2011); reduce 
tissue lesion volume (Widenfalk et al., 2003); increase white matter (Facchiano et 
al., 2002) and gray matter (Figley et al., 2014) sparing; promote neuritogenesis 
into the lesion (des Rieux et al., 2014); decrease glial scar (Widenfalk et al., 
2003); and improve locomotion (Facchiano et al., 2002; Kim et al., 2009; Liu et 
al., 2009; Yamaya et al., 2014). 
However, the time window of treatment onset, number of doses and 
duration of treatment, and VEGF dosage are crucial factors in employing this 
trophic factor following SCI, as some studies have reported exacerbation of 
lesion and decreased motor performance compared to controls (Benton and 
Whittemore, 2003), aberrant excessive sprouting of axons (Nesic et al., 2010) 
and increased mechanical allodynia (Nesic et al., 2010; Sundberg et al., 2011).  
Drs. Benton and Whittemore administered a supraphysiological dosage of VEGF 
(0.5 µg/µL) at 3 days post injury; considering the peak of the inflammatory phase 
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and the very high VEGF dosage, it is reasonable to have observed exacerbation 
of lesion, likely due to excessive vascular permeability and extravasation of 
inflammatory mediators.  It is unknown whether the increased mechanical 
allodynia in these studies is a result specifically of VEGF165 or perhaps VEGF188, 
as suggested by Nesic et al. (2010).  However, it is noteworthy that a subset of 
saline injected SCI control animals also developed mechanical allodynia 
(Sundberg et al., 2011) similar to other studies (Figley et al., 2014).  Thus, VEGF 
may just be one of the key players involved in mechanical hypersensitivity after 
SCI.  Interestingly, van Neerven et al. (2010) had a similar route of intrathecal 
VEGF administration as Sundberg et al. (2011); however, van Neervan gave 
daily injections for the first week post-SCI while Sundberg’s group gave only one 
injection immediately following injury.  Sundberg and colleagues observed 
exacerbated forepaw mechanical allodynia (Nesic et al., 2010); yet van Neervan 
and colleagues observed a decrease in mechanical allodynia of the hindpaw 
(2010).  Additionally, Figley et al. (2014) reported significantly decreased 
mechanical allodynia in VEGF treated rats compared to saline or viral vector 
vehicle controls.  Observed differences across these studies are likely due to the 
duration of VEGF administration and dosages. 
In a study of cerebral ischemia, Manoonkitiwongsa et al. (2004) reported 
neuroprotection with low (2µg) and medium (8µg) doses of VEGF165, 
subthreshold to promote angiogenesis.  However, higher (60µg) doses of 
VEGF165 resulted in angiogenesis without neuroprotection in ischemic brains and 
neuronal injury in VEGF165 treated non-ischemic (uninjured/normal) brains.  This 
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study further demonstrates the crucial aspect of VEGF dosage, in addition to 
timing, particularly for studies targeting angiogenesis and neuroprotection 
concomitantly.  Shinozaki et al. (2014) investigated the contributions of VEGFR-1 
and VEGFR-2 activation on neuroprotection following SCI, through neutralizing 
antibodies, and determined VEGFR-1 plays a major role in vascular permeability, 
while VEGFR-2 promotes neuron survival.  
VEGF Combinational Therapies for SCI Repair 
Similar to other neuroprotective and neural regeneration therapies, VEGF 
alone might be insufficient to produce significant axon regeneration/sparing, 
functional synapse formation, and improved functional recovery following SCI.  
Thus, further investigation of VEGF is necessary, and more studies are 
employing VEGF as part of combinational treatments.  In 2012, Lutton et al. 
showed reduced lesion cavity, glial scar density, and the inflammatory response 
(macrophage/microglia) in response to VEGF and PDGF following SCI.  This 
combination of trophic factors (VEGF and PDGF) was also shown to promote 
improved functional recovery following SCI (Chehrehasa et al. 2014).  Gong et al. 
(2015) observed neuroprotection of spinal cord neurons through VEGFR-2 (Flk-
1), after application of the endothelin-A/B dual receptor antagonist (Bosentan).  In 
a 2011 combinational study (de LaPorte et al.), poly (lactide-co-glycolide) (PLG) 
bridges loaded with VEGF and FGF-2 (fibroblast growth factor 2) promoted 
neurite growth and angiogenesis within the lesion site, and prevented the 
formation of cystic cavity.  Additional trophic factors might be necessary in order 
to promote significant axonal re-growth and functional recovery. 
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VEGF Neuroprotection in Neurodegenerative Disease Models 
Dysfunctional vasculature or aberrant VEGF levels negatively influence a 
number of neurodegenerative diseases including Alzheimer’s disease, 
Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease), Huntington’s 
disease, Parkinson’s disease, and stroke (Storkebaum and Carmeliet, 2004b).  In 
a mouse model of epilepsy, VEGF administration preserved learning and 
memory function (Morris water maze) and reduced anxiety-like behaviors that are 
typically observed in status-epilepticus rodents (Nicoletti et al., 2010).  Reduced 
VEGF levels and deletion of the HRE (hormone response element) in the VEGF 
promoter (Oosthuyse et al., 2001) can both lead to rodent ALS-like phenotypes: 
decline of motor function and decreased grooming behavior in a SOD1 
(Superoxide dismustase 1) mouse model of ALS (Carmeliet & Ruiz de 
Almodovar, 2013).  Moreover, in similar studies of human patients, Carmeliet & 
Ruiz de Almodovar (2013) and Lambrechts et al. (2003) determined that human 
ALS patients had lower VEGF levels compared to healthy population-based 
controls, with the lowest VEGF serum levels correlating with the greatest ALS 
susceptibility (Lambrechts et al., 2003).  Additionally, VEGF was shown to be 
neuroprotective in rodent models of Parkinson’s disease (Herran et al., 2013), 
ALS (Azzouz et al., 2004), Huntington’s disease (Emerich et al., 2010), and 
cerebral ischemia (Sun et al., 2003; Manoonkitiwongsa et al., 2004).  
Interestingly, VEGF-A165 competes with Semaphorin 3A for signaling through 
the neuropilin-1 receptor.  VEGF promotes axonal outgrowth and 
chemoattraction while Semaphorin 3A influences axonal guidance by 
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chemorepulsion, axon pruning, and growth cone collapse (Zachary et al., 2005).  
Thus, inhibition of Semaphorin 3A is another putative target for SCI therapies for 
promoting axonal outgrowth via VEGF-A165, making this a potential 
combinational treatment approach worth investigating. 
VEGF Signaling for Neuroprotection in SCI 
VEGF also influences many cell types, including neurons (Kawai et al., 
2006; Jin et al. 2006; Ruiz de Almodovar et al. 2009), Schwann cells (Sondell et 
al., 1999), astrocytes (Krum et al., 2002; Mani et al. 2010), microglia, neuronal 
stem cells (Maurer et al., 2003; Meng et al., 2006), and oligodendrocyte 
precursors, to promote angiogenesis, neurogenesis (Sun et al. 2006), 
dendritogenesis, synaptic plasticity, axon growth and guidance, cell survival (Sun 
et al. 2003), proliferation (Zhu et al. 2003), migration, differentiation, 
neuromuscular junction innervation, and neuroendothelial junction maintenance.  
Jin et al. (2000) detailed the neuroprotective effects of hippocampal neurons by 
VEGF activation of VEGFR-2, and downstream signaling of PI3K, with reduced 
caspase-3.  Hao and Rockwell (2013) showed the neuroprotection of 
hippocampal neurons via signaling through VEGF activation of VEGFR-2, with 
downstream signaling through the PI3K/Akt and MEK/ERK pathways.  This study 
also suggests that VEGFR-1 and NP-1 likely serve as backup signaling pathways 
for neuroprotection with blockade of VEGFR-2.  The pleiotropic mechanisms of 
VEGF are summarized in Figure 4, as well as Storkebaum et al. (2004a), 
Nowacka and Obuchowicz et al. (2012), and Carmeliet and Ruiz de Almodovar 
(2013). 
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Conclusion 
Since the discovery of VEGF in early 1970’s, by Dr. Judah Folkman 
(Folkman et al., 1971) and its official naming by Drs. Ferrara and Henzel (Ferrara 
et al., 1989), it has been determined that this vascular trophic factor has much 
broader implications than its canonical role in development of the vascular 
system.  VEGF’s pleiotropic mechanisms include: angiogenesis (Folkman et al. 
1971; Carmeliet et al., 1996), axonal guidance (Ruiz de Almodovar et al., 2011; 
Carmeliet & Ruiz de Almodovar et al., 2013; Zachary et al., 2005), 
neuroprotection (Storkebaum et al., 2004a; Facchiano et al., 2002; Widenfalk et 
al., 2003; Zacchigna et al., 2008), Schwann cell survival and migration, and 
proliferation of astrocytes, microglia, and neural stem cells (Storkebaum et al., 
2004a).  Moreover, deletions within the VEGF promoter region cause a 
neurodegenerative phenotype in mice, similar to Amyotrophic Lateral Sclerosis 
(ALS), showing VEGF is important for maintenance of motor function (Oosthuyse 
et al., 2001).  Additionally, Lambrechts et al. (2003) showed motoneuron 
protection by VEGF administration in an ALS mouse model.  This study also 
showed that VEGF serum levels in European patients correlated with ALS 
susceptibility, with lower circulating VEGF levels correlating with higher risk of 
sporadic ALS.  VEGF delivered via a retroviral vector delayed disease onset, 
promoted neuroprotection, and prolonged survival of animals with an ALS 
phenotype (Azzouz et al., 2004).  Similarly, VEGF delivered 
intracerebroventricularly prolonged the survival period, delayed the disease 
onset, and spared motor neurons in an ALS model (Storkebaum et al., 2005). 
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After spinal cord injury, an angiogenic response occurs that peaks 
approximately 7-14 days post-injury, and regresses coincident with the onset of 
cystic cavitation, in both rats and higher primates (Loy et al., 2002; Casella et al., 
2002; Benton et al., 2008a; Fassbender et al., 2011).  Intact vasculature is crucial 
for delivering oxygen and nutrients to the tissues and for removing toxic wastes.  
In studies of SCI, VEGF has been shown to: 1) promote angiogenesis 
(Facchiano et al., 2002; Figley et al., 2014; des Rieux et al., 2014), 2) decrease 
the glial scar (Widenfalk et al., 2003), 3) increase white matter sparing 
(Facchiano et al., 2002), 4) increase gray matter  sparing (Figley et al., 2014), 5) 
promote neuroprotection (Facchiano et al., 2002), 6) promote neuritogenesis into 
the lesion (des Rieux et al., 2014), 7) promote oligodendrogenesis and improved 
myelin integrity (Sundberg et al., 2011), 8) reduce tissue lesion volume 
(Widenfalk et al., 2003), and 9) promote improved locomotion (Facchiano et al., 
2002; Kim et al., 2009; Liu et al., 2009; Yamaya et al., 2014).    Therefore, VEGF 
appears to be a promising target for repair of the injured nervous system, due to 
trauma and degenerative diseases. 
However, the main factors for consideration in applying this trophic factor 
in models of SCI are time point of administration and VEGF concentration, as 
some studies have observed exacerbation of SCI lesion (Benton and 
Whittemore, 2003), likely due to early time point after SCI insult and 
supraphysiological doses of VEGF.  It is also important to consider that VEGF 
administered alone might be insufficient to promote neuroprotection, axon 
regeneration/sparing, functional synapse formation, and improved functional 
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recovery following SCI.  Current literature suggests that VEGF in combination 
with other therapeutic approaches for SCI appears to hold the greatest potential 
for promoting angiogenesis, neuroprotection, axonal regeneration, and functional 
recovery (de LaPorte et al., 2011; Chehrehasa et al., 2014; Gong et al., 2015). 
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Figure 4.  VEGF Pleiotropism.  Influence of VEGF on vasculature, neurons, 
neural stem cells, and glial cells (astrocytes, Schwann cells, microglia, and 
oligodendrocyte precursors). 
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PART II: Glial cell line-derived Neurotrophic Factor and Spinal Cord Injury 
SCI Background and Need for Therapies 
Spinal cord injury (SCI) is a devastating chronic condition for which no 
effective treatments currently exist.  Singh, Fehlings et al. (2014) conducted a 
systematic review of global statistics, beginning with 5,874 articles with a final 
inclusion of 48 articles, reporting worldwide SCI statistics, with the United States 
having the highest prevalence (906 cases per 1 million people); New Zealand 
having the highest reported national incidence (49.1 cases of SCI per 1 million 
people); and Spain (8 cases of SCI per 1 million people) and Fiji (10 cases of SCI 
per 1 million people) showing the lowest national incidences.  The primary cause 
of SCI cases worldwide is motor vehicle accidents, followed by falls and sports 
injuries, for most countries (Singh et al., 2014).  The long-term potential of 
chronic pain, inflammation, and devastating disabilities that SCI patients endure 
are compounded by the extensive lifetime costs of care.  Approximately 1 - 4.5 
million United States dollars is spent over the lifetime of an SCI patient, 
depending upon the patient’s age and level of injury (Christopher Reeve 
Foundation website, NSCISC – National Spinal Cord Injury Statistical Center).  
The national cost in the United States is estimated at more than $400 billion US 
dollars for current and future healthcare for patients suffering from SCI. 
The initial SCI mechanical trauma disrupts local vasculature and leads to 
a breakdown of the blood-spinal cord barrier (Noble and Wrathall, 1987; 
Popovich et al. 1996; Schnell et al., 1999).  This is followed by secondary wave 
of injury (Schwab and Bartholdi, 1996), comprised of hemorrhage, microvascular 
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dysfunction (Fassbender et al., 2011), ischemia (Tator and Fehlings, 1991), 
excitotoxicity, edema, neuronal apoptosis, loss of gray and white matter tissue 
(Tator and Koyanagi, 1997), axonal die-back, chronic inflammation (Mautes et 
al., 2000; Oudega 2013; Blomster et al., 2013), and the formation of a dense 
astrocytic glial scar.  During the acute phase after SCI, the astrogliosis is 
presumed to contain the spread of excitotoxic molecules, thus limiting the lesion 
area.  However, in chronic phases after SCI, this inhibitory scar impedes axonal 
regeneration and tissue repair by surrounding the lesion area and creating a 
structural border, separating injured from spared tissue.  Literature has shown 
GDNF’s promising influence on reducing astrogliosis (Iannotti et al., 2003; Deng 
et al., 2011a; Ansorena et al., 2013), in addition to its known neuroprotective 
effects, thus making astrocytes a target for potential therapies for SCI. 
Discovery of GDNF Family Ligands and Receptors 
The Glial cell line-derived neurotrophic factor (GDNF) subfamily of 
neurotrophic ligands consists of GDNF, neurturin (NRTN), artemin (ARTN), and 
persephin (PSPN), which bind to the glycosylphophatidylinositol-anchored GFRα 
receptors 1-4, respectively (Trupp et al., 1998).  The molecular structures of the 
GDNF family ligands and receptors are nicely detailed by Wang (2013), as well 
as in Figure 5.  While ARTN (Widenfalk et al., 2009; Wong et al., 2015), NRTN 
(Buj-Bello et al., 1997; Horger et al., 1998; Golden et al., 2003), and PSPN 
(Tomac et al., 2002; Milbrandt et al., 1998) have all been shown to be 
neuroprotective, this chapter focuses specifically on GDNF and its applications 
for the treatment of spinal cord injury (SCI).   
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GDNF was first identified as a neurotrophic factor released from glial cells 
by Engele et al. (1991) and Lin. et al. (1993), in its promotion of the survival of 
dopaminergic neurons.  The GFRα-1 receptor was first reported in Cell in 1996 
(Jing et al.), following its isolation, cloning, and characterization from rat retinal 
cells; a study which also detailed the interaction between GDNF, GFRα-1, and 
the cRET receptor.  Interestingly, the following week a Nature publication 
(Treanor et al., 1996) revealed concurrent work with similar findings on a cloned 
and characterized GFRα-1, as well as the GDNF, GFRα-1, and cRET multi-
subunit receptor complex.  
Localization of GDNF and its Receptors 
Expression patterns of GDNF, GFRα-1, and cRET indicate that the three 
are not mutually exclusive for GDNF’s trophic actions, as GFRα-1 is expressed in 
regions lacking cRET, and cRET has expression in regions lacking GFRα-1 
expression, well-characterized by Trupp et al. (1997).  In 1996, Trupp et al. 
identified GDNF’s activation of the cRET proto-oncogene, resulting in neuronal 
survival, while Jing et al. (1996) identified GFRα-1 as mediating the interaction 
between GDNF and cRET.  In 2001, Nicole et al. demonstrated the expression of 
GDNF mRNA and protein, as well as GFRα-1 and cRET on both neurons and 
astrocytes.  Heparan sulphate, a key glycosaminoglycan, was identified as 
crucial for the phosphorylation of the c-Ret co-receptor, thus, also necessary for 
GDNF signaling through its GFRα-1 receptor (Barnett et al. 2002). 
Satake et al. (2000) showed a dramatic upregulation of GDNF mRNA 
expression within 3 hours post SCI that was maintained for approximately 2-4 
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weeks following injury.  Additionally, changes in GDNF’s expression pattern 
following CNS injury are nicely illustrated by Trupp et al. (1995, 1997) and 
Donnelly and Popovich (2008).  GDNF targets in the CNS and PNS, as well as 
the administration of GDNF gene therapy for motoneuron protection were nicely 
highlighted in a review by Bohn (2004). 
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Figure 5. GDNF Family of Ligands and Receptors.  GDNF binds to GFRα-1, 
NRTN binds to GFRα-2, ARTN binds to GFRα-3, and PSPN binds to GFRα-4.  
GFRα 1-4 bind to cRET co-receptors. 
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GDNF Promotes Cell Survival and Growth 
One of the earliest studies to report GDNF induced reduction of 
astrogliosis was a study by Trok et al. (1996), in which spinal cord explants were 
allotransplanted into Sprague-Dawley anterior eye chambers.  GDNF was shown 
to promote graft survival and growth, in addition to the reduced GFAP 
immunoreactivity.  Klocker et al. (1997) identified a new subpopulation of 
neurons responsive to GDNF in a study showing significantly reduce cell death of 
axotomized retinal ganglion cells in response to GDNF treatment.  The 
upregulation of GDNF in the distal portion of peripheral injured nerves was 
assessed and quantified, along with the localization of its cRET receptor, as 
reported by Bar et al. (1998).  Similarly, Hoke et al. (2002) showed upregulation 
of GFRα1 receptor on the distal segment of the sciatic nerve following injury; this 
upregulation and the upregulation of GDNF by Schwann cells was maintained for 
approximately six months following injury.  The GFRα1 receptor was localized to 
peripheral Schwann Cells in a study by Hase et al. (2005), showing another 
target of GDNF for the repair of injured nervous system.  Arce et al. (1998) 
reported a 75% inhibition of neuron survival after exposure to Schwann cell 
cultured media containing a blocking antibody against GDNF.  This study 
demonstrates the importance of GDNF for the Schwann cell-mediated 
neuroprotection.  Paratcha et al. (2001) highlighted the recruitment of cRET to 
neuronal cell membrane lipid rafts, in response to soluble GFRα1.  Rind et al. 
(2002) showed anterograde transport of GDNF in dorsal root ganglion (DRG) and 
motor neurons, both with undetectable levels of GDNF mRNA in their current 
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state.  The radiolabeled GDNF in this study was provided to the DRGs and motor 
neurons and by Schwann cells and oligodendrocytes, respectively.  In 2004, a 
novel in vivo study was published showing for the first time the endogenous 
release of GDNF from astrocytes, which was neuroprotective to neighboring 
neuronal populations, in utero during development (Zhao et al.). 
GDNF Signaling for Cell Survival 
In addition to its neuroprotective effects (Oppenheim et al., 1995; Beck et 
al., 1995; Tomac et al., 1995), GDNF has also been shown to: 1) attenuate 
astrocyte cell death via reduced activation of caspase-3 (Yu et al., 2007) as well 
as through caspase-3/Akt independent mechanisms (Chu et al., 2008); 2) 
minimize activation of microglia and production of nitric oxide (Xing et al., 2010; 
Hermann et al., 2001); and 3) promote the survival (Liu et al., 2014) and 
proliferation (Hoke et al. 2003; Zhang et al., 2009) of Schwann cells.  GDNF 
activates rat primary cortical microglial cells through GFRα-1 and cRET 
receptors, with downstream signaling through the MAPK pathway, as illustrated 
in a study by Honda et al. (1999).  This study demonstrates microglia as another 
putative therapeutic target for GDNF in CNS injury and disease.  However, a pro-
inflammatory response, resulting in increased levels of IL-1β likely led to the 
GDNF neuroprotection observed in a lipopolysaccharide (LPS)-induced nigral 
degeneration model of Parkinson’s disease (Iravani et al., 2012). 
Soler et al. (1999) characterized the downstream signaling of GDNF in 
motoneurons, which includes activation of both the PI3K and ERK-MAPK 
pathways.  Further investigation revealed that the neuroprotective effects of 
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GDNF signaled through the PI3K pathway (Soler et al., 1999).   In 2001, Nicole 
et al. described a novel mechanism of cortical neuroprotection from 
excitotoxicity-induced necrotic cell death after GDNF application; however, in this 
study GDNF failed to rescue cortical neurons from apoptotic cell death.  
Moreover, this study illustrated the indispensable nature of the MAPK (MEK) 
pathway, and GDNF’s reduction of NMDA-triggered calcium influx, resulting in 
the attenuation of necrotic cell death.  However, glutamatergic excitotoxicity 
induced by non-NMDA agonists (AMPA and kainate) was unable to be 
attenuated by GDNF administration (Nicole et al., 2001).  Additionally, this study 
highlighted GDNF’s neuroprotective effects were likely through diminished NMDA 
receptor activity and not the result of free radical scavenging.  Cheng et al. 
(2002) investigated the downstream neuroprotection signaling of GDNF and 
determined that GDNF activated the MAPK signaling pathway and resulted in 
increased levels of Bcl-2.  Liu et al. (2014) described a similar upregulation of 
Bcl-2 and downregulation of Bax, which provided neuroprotection in vitro and 
Schwann cell survival in vivo, in rats treated with Schwann cells overexpressing 
GDNF, as compared to SCI rats. 
Studies Employing GDNF for SCI Repair 
After avulsion injury, axotomized motoneuron cell death was reduced by 
50% and somatic atrophy was reduced, after treatment with GDNF (Li et al., 
1995).  In another study of avulsion injury, GDNF administered via AAV-viral 
vector significantly attenuated spinal cord ventral horn motor neuron death 
(Watabe et al., 2000).  In one of the earliest studies of GDNF administration after 
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SCI, Ramer et al. (2000) reported the ability of GDNF to rescue spinal cord 
motoneurons.  In a contusive SCI model, GDNF showed significant improvement 
in motor function (Basso, Beattie, Bresnahan, BBB locomotor rating scale), 
increased cell survival and number of spared neuronal fibers compared to PBS-
controls (Cheng et al., 2002).  
Iannotti et al. (2004) reported significantly increased spared white matter 
and significantly attenuated lesion volume in response to GDNF administration 
via an osmotic minipump, following contusive SCI.  Quite noteworthy, Mills et al. 
(2007) described the GDNF enhancement of axonal regeneration occurs within a 
narrow therapeutic dosage range.  In a compressive clip model of SCI, Kao et al. 
(2008) demonstrated significantly improved motor functional recovery (inclined 
plane), significantly reduced infarct zone, a dramatic increase in the number of 
VEGF-positive  and GDNF-positive cells (undetectable in sham and SCI-only 
groups), and significantly reduced TUNEL staining. 
GDNF Combinational Therapies for SCI Repair 
Iannotti et al. (2003) showed robust remyelination, axonal regeneration, 
and reduced cavitation, as well as modest yet significantly reduced astrogliosis 
and immune infiltration, in response to GDNF releasing matrigel guidance 
channels transplanted following hemisection SCI.  Additionally, there was 
synergistic promotion of axonal regeneration and myelination in response to 
guidance channels containing both Schwann cells (SCs) and GDNF (Iannotti et 
al., 2003).  Despite significant axonal regrowth into the SCI lesion site 
accompanied by the recruitment of myelinating Schwann cells, Blesch and 
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Tuszynski (2003) highlighted the difficulty of promoting axonal regrowth through 
and beyond the lesion site, following secretion of GDNF from genetically 
modified, transplanted fibroblasts.  In a novel study of chronic spinal cord injury, 
using a peripheral nerve graft, GDNF treatment enhanced axonal regeneration 
by 7-fold compared to controls (Dolbeare and Houle, 2003).  In a study with 
Schwann cell seeded-guidance channels (Zhang et al., 2009) observed 
significantly enhanced axonal regeneration, myelination, and number of blood 
vessels within the regenerated tissue.  GDNF was also shown to increase the 
diameter of the regenerated axons in this study (Zhang et al., 2009).    
The inhibitory astrogliosis was positively modulated and an intermingling 
of host and graft tissue was observed at the hemisection lesion interface, in a 
combinational study of GDNF and Schwann cells (SCs) in semi-permeable 
guidance channels (Deng et al., 2011b).  In a moderate, contusive, midline SCI 
study, we observed a harsh glial scar border juxtaposed to the host spinal cord 
tissue after administration of saline, our novel hydrogel (non-immunogenic, in situ 
gelable, bioengineered hydrogel comprised of a multi-arm thiolated polyethylene 
glycol, thiolated laminin-derived loopshaped short peptide sequences (CDPVCC 
GTARPGYIGSRGTARCCAC), thiolated hyaluronan, and thiolated 
recombinant human collagen; Li et al., 2013; 2014), and hydrogel + brain-derived 
neurotrophic factor (BDNF).  In contrast, in the presence of GDNF an 
intermingling of glial fibers into the host spinal cord tissue (Figure 6) occurred (Xu 
unpublished).  Another notable study was performed by Zhao et al. (2004) in 
which GDNF reduced axotomy-induced astrogliosis of the facial nerve.  In a more 
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recent study, a growth-promoting bridge was formed by transplantation of 
Schwann cell-seeded guidance channels, with Schwann cells overexpressing 
GDNF (Deng et al., 2013).  This GDNF overexpression modulated the inhibitory 
astrocytic glial scar, created a more permissive environment for propriospinal 
axonal regrowth through and beyond the distal end of the lesion, conducted 
electrical signals through the lesion gap, and improved functional recovery (Deng 
et al., 2013).  This study highlights the importance of combinational treatment 
approaches for traumatic spinal cord injury. 
In another combinational treatment approach, GDNF was embedded into 
an alginate hydrogel for slow release and employed in a hemisection SCI model 
(Ansorena et al., 2013).  In this study, GDNF promoted increased functional 
recovery, increased numbers of intralesional and perilesional neurites, reduced 
astrogliosis, and increased intralesional vasculature, as compared to controls.  
Using PLGA (polylactide-co-glycolic acid) microspheres for slow release, Zhang 
et al. (2013) administered GDNF, Chondroitinase ABC, and a Nogo A antibody 
following a transection SCI.  Lu et al. (2012) showed remarkably robust axonal 
regeneration up to 12mm in length, in a severe SCI transection model (2mm of 
cord removed), with a combinational treatment approach including 
transplantation of neural stem cells in fibrin matrices containing a trophic factor 
cocktail (GDNF, BDNF (brain-derived neurotrophic factor), PDGF-AA (platelet-
derived growth factor), NT3 (neurotrophin-3), IGF-1(insulin-like growth factor 1), 
EGF (epidermal growth factor), aFGF (acidic fibroblast growth factor), bFGF 
(basic fibroblast growth factor), HGF (hepatocyte growth factor), and calpain 
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inhibitor/MDL28170).  Moreover, this tissue graft resulted in: 1) significantly 
enhanced motor recovery, 2) significantly improved electrical signals across the 
lesion gap, 3) survival and differentiation of the neural stem cells, 4) an 
intermingling of host axons into tissue grafts, 5) increased myelination, and 6) 
functional synapse formation likely leading to the observed significant 
improvement in locomotion (Lu et al., 2012).  Collectively, these studies 
demonstrate the high potential of GDNF, particularly in combinational treatment 
approaches, for use for repair of the injured spinal cord. 
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Figure 6.  GDNF Modulation of the Inhibitory Glial Scar.  A harsh border 
was observed with administration of Saline (A), Hydrogel (D), and   Hydrogel + 
BDNF (B) after midline contusive SCI.  Contrasted by a more permeable glial 
border with glial fibers appearing to intermingle with host lesion tissue in the 
presence of added GDNF, Hydrogel + GDNF (E), and Hydrogel + BDNF + 
GDNF (C). 
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PART III: Hydrogel, VEGF, and GDNF for Spinal Cord Injury Repair 
Bioengineered Tissues and SCI 
Bioengineered tissues serve as both structural and functional scaffolding 
matrices, through their capacity to serve as reservoirs for various 
pharmacological reagents, growth factors, and enzymes that would otherwise 
be broken down within minutes-to-hours within the lesion environment.  
Bioengineered tissues can be designed and synthesized to have various 
viscosities, rheological properties, and electrospun parameters for fiber 
alignment.  The hydrogel used in this study was designed to match the tensile 
strength of the spinal cord (Li et al., 2013; 2014), and to have a release profile 
of approximately 3-4 weeks of embedded trophic factors (Figure 12; Xuejun 
Wen, unpublished). 
Bioengineered tissues have been utilized for models of SCI primarily over 
the past two decades.  Woerly and colleagues synthesize and transplanted a 
novel biocompatible hydrogel (Neurogel™) comprised of poly(N-[2-
hydroxypropyl]methacrylamide) into a 3mm transection gap at the 5th thoracic 
cord, and observed angiogenesis and axonal regrowth into the bioimplant 
(2001b).  Similarly, a study employing a bioengineered poly(D,L-lactic acid) 
guidance channel observed increased angiogenesis and neuron survival, 
following a 4mm thoracic complete transection SCI (Patist et al., 2004).  
Hurtado et al. (2011) observed robust axonal alignment and regeneration (up to 
2mm) from a poly-L-lactic acid microfiber-based conduit, inserted into a 3mm 
gap in the thoracic spinal cord, after complete transection.  Through the use of a 
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poly(ethylene glycol)-poly(serinol hexamethylene urethane) bioengineered 
tissue, Ritfeld et al. (2014) demonstrated improved functional recovery, 66% 
increase in spared spinal cord tissue, and enhanced survival of the transplanted 
bone marrow stromal cells.  This study displays the use of bioengineered 
tissues as matrices for transplanted cells, and promotes the combinational use 
of bioengineered tissues, beyond just structural scaffolds or reservoirs for 
trophic factor release.  Other recent studies utilizing bioengineered tissues also 
demonstrate the importance of combinational therapies for SCI repair.  For 
example, Rauck and colleagues (2015) observed that their novel poly(ethylene 
argininylaspartate diglyceride) and heparin coacervate did not provoke an 
immune response and nor did it affect the glial scar, axon density, or neuron 
sparing.  Another beneficial aspect of this bioengineered tissue was that in 
combination with Sonic Hedgehog it decreased the intensity of the glial scar 
(Rauck et al., 2015), thus, creating a more permissive environment for tissue 
repair. 
Dr. Peter Carmeliet has been vital in expanding and detailing the Belgian 
Anatomist, Andreas Vesalius’ 1543 observations (De humani corporis fabrica, On 
the fabric of the human body, 1543) about the overlap of the nervous and 
vascular systems, thus, displaying the pleiotropic influence of VEGF on the 
nervous, vascular, and immune systems (Carmeliet and Tessier-Lavigne, 2005).  
The neurovascular evolution of VEGF and its influence on the nervous system 
was summarized by Zacchigna, Carmeliet and colleagues (2008), displaying the 
importance of the human VEGF homologue in C. elegans (Caenorhabditis 
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elegans) and Drosophila melanogaster, which lack blood vessels or have very 
few, respectively.  Additionally, Popovici et al. (2002) described receptors on C. 
elegans neurons with structural similarity to the human VEGF receptors 
(VEGFR’s), which can activate human VEGFR’s (Zacchigna et al., 2008). 
Rationale 
We employed a novel, non-immunogenic, in-situ gelable bioengineered 
hydrogel to serve as a structural support matrix for growing axons, blood vessels, 
and astrocytic processes.  This hydrogel then served as a functional reservoir 
with a time-controlled release of both VEGF and GDNF, and was designed to 
have an approximate release profile of 3-4 weeks (Figure 12; Xuejun Wen, 
unpublished).  The biodegradable nature of our hydrogel along with the 
breakdown of VEGF and GDNF (by endogenous enzymes) give the treatment 
profile a terminal point, thus relieving any concerns of unregulated trophic factor 
administration, unregulated cell growth or tumor formation, which exist when 
using viral vector administration or cells genetically modified to overexpress 
trophic factors.  The overall aim of this study was to create a permissive 
environment for lesion revascularization, neuronal and axonal sparing, tissue 
regrowth, and ultimately for functional recovery, after a moderate thoracic 
contusive SCI. 
Preliminary data from pilot studies, with hydrogel transplanted at 2 days 
(acute phase), 7 days (subacute phase), and 4 weeks (chronic phase) post SCI, 
reflected that 7 days post SCI is a more optimal transplantation time point than 
either 2 days or 4 weeks (Figures 7 and 8).  These time points were chosen in 
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order to determine the optimal time window of transplantation post SCI.  Due to 
the inflammatory wave of secondary tissue damage after SCI, and the fact that 
the onset of cystic cavitation occurs at approximately 7 days post SCI.  Anywhere 
from 7-14 days post SCI is on the tail-end of the inflammatory phase, and the 
beginning stages of cavitation and glial scar formation. 
After performing a moderate, midline, thoracic contusive SCI with various 
transplantation time points for saline and hydrogel, we concluded that the 
hydrogel might be exacerbating the lesion area with transplantation at 2 days 
post SCI due to the fact that the onset of cavitation typically occurs at 
approximately 7 days post SCI (Figures 7 and 8).  Thus, at 2 days post SCI, the 
cavity may not be developed to hold the hydrogel.  Therefore, injection of 3-4 µL 
of fluid that will then become semi-solid as it reaches body temperature, will 
compress the adjacent spinal cord tissues, and cause more injury than tissue 
protection or repair.  Since the hydrogel is proposed to serve primarily as a 
structural support network for the injured spinal cord, 4 weeks post SCI is in the 
chronic injury stage, and the transplanted hydrogel may not confer any reduction 
in lesion area or cavity size.  Seven days post SCI is the onset of cavitation, the 
onset of angiogenic vascular regression, and is at the tail-end of the inflammatory 
response as well as the early stages of the astrocytic (glial wall) response 
following injury (Donnelly and Popovich 2008). 
Based on the pilot studies discussed above (Figures 7 and 8), we chose a 
transplantation time point of 7-8 days post SCI.  However, in an attempt to 
minimize inflammation following SCI, 12 days post SCI was chosen for the 
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transplantation time point of the last study (Table 3).  Most of the axonal regrowth 
observed will therefore be a result of axonal sparing or sprouting as opposed to 
neuroprotection, due to the 12 day transplantation time point which is late 
enough in the secondary phase of injury that not much neuroprotection is 
occurring. 
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Figure 7. Histology of Hydrogel Transplantation Time 
Course Study.  Saline (Vehicle) transplanted at 2 days (A), 7 
days (B), and 4 weeks (C) post moderate, midline, contusive 
SCI.  Hydrogel transplanted at 2 days (D), 7 days (E), and 4 
weeks (F) post moderate, midline, contusive SCI. 
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Figure 8. Quantification of Hydrogel 
Transplantation Time Course Study.  (A) 
Lesion volume as percent of total cord 
volume.  (B) Cavity volume as percent of total 
cord volume.  (C) Cavity volume as percent of 
total lesion volume. V = Saline (Vehicle), H = 
Hydrogel, 2D = 2 days, 7D = 7 days, and 4W 
= 4 weeks. 
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Materials and Methods 
All animal procedures were performed in accordance with the approved 
Institutional Animal Care and Use Committee of the Indiana University School of 
Medicine guidelines (Protocol #10406).   
In vitro Neurite Outgrowth of Spinal Cord Neurons 
Embryonic day 15 (E15) spinal cord neurons were isolated from Sprague-
Dawley embryonic rats (Harlan, Indianapolis, IN) from a previously established 
protocol (Jiang et al., 2006).  Briefly, E15 rat spinal cords were isolated and 
placed in Leibovitz’s L-15 medium (Gibco).  Meninges were carefully removed.  
Spinal cords were cut into small pieces, dissociated with 0.05% trypsin/EDTA for 
15-20 min at 37oC, and then gently triturated.  Neurons were placed in 37oC for 
30 minutes, to allow for adherence and to eliminate glial cells and fibroblasts.  
Neurons were then plated on poly-L-lysine pre-coated 48-well plates (Corning® 
CellBind® Surface) at a density of 280,000 cells/well, and incubated in a 
humidified atmosphere containing 5% CO2  (37oC), DMEM + 10% heat-
inactivated fetal calf serum + 5% heat-inactivated horse serum + 2 mM 
glutamine.  After 16 hours, medium was replaced with Neurobasal medium with 
2% B27, 1% N2 and 2 mM glutamine (all from Life Technologies, Inc.).  The 
purity of the cell culture was evaluated and estimated to be approximately 94% 
neurons.  Forty-eight hours after plating, the medium (Neurobasal 2% B27 and 
1% N2) was refreshed (half-on), and trophic factors were added (VEGF and 
GDNF) for treatment group wells.  Neuronal control wells received half-on 
refreshed media only at this time point.  Groups consisted of the following: 1) 
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neuronal (medium) controls, 2) VEGF 25 ng/mL, 3) VEGF 50 ng/mL, 4) GDNF 25 
ng/mL, 5) GDNF 50 ng/mL, 6) VEGF 25 ng/mL + GDNF 25 ng/mL, and 7) VEGF 
50 ng/mL + GDNF 50 ng/mL.  72 hours later, cells were fixed with 4% PFA.  Cells 
were then stained for β-tubulin (neurites) and Hoechst 33342 (1:100; Invitrogen; 
nuclear marker), with FITC (Fluorescein isothiocyanate) secondary antibody 
used for detection of β-tubulin.  Cells were imaged using the ImageXpress® 
Micro XL (Figure 11), and 90 cells per treatment group were analyzed using the 
MetaXpress® 5.1 software (Molecular Devices). 
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Figure 9.  Neurite Outgrowth of E15 Spinal Cord Neurons.  (A) Neurite 
outgrowth stained with β-tubulin (green) and Hoechst (blue), top row; computer 
software (MetaXpress®) generated pseudo-color schematic of outgrowth from 
individual neurons, bottom row).  Neuronal controls are neurons with media that 
does not contain added VEGF or GDNF.  (B) Total Neurite Outgrowth.  (C) 
Mean Process Length.  (D) Mean Number of Branches.  (E) Maximum Process 
Length.  (F) Larger image of (A).  (n = 90 neurons per treatment group, all from 
one plating.  All images are 20x magnification.  All data include SEM, * p < 0.05, 
** p < 0.01, *** p < 0.001). 
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Figure 10.  Neuroprotection by VEGF and GDNF.  VEGF and GDNF resulted 
in significantly more E15 neurons, which appears to be largely an influence of 
VEGF, with a dramatic increase in neuron number for the combined VEGF + 
GDNF group at higher concentrations. 
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Figure 11.  ImageXpress®.  Neurons stained for β-tubulin and Hoechst for 
visualization of neurite outgrowth via ImageXpress® device as well as MetaXpress 
software. 
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In vivo Hydrogel Combinational Therapy for SCI 
Novel Bioengineered Hydrogel 
A novel, non-immunogenic, in situ gelable, bioengineered hydrogel 
comprised of a multi-arm thiolated polyethylene glycol, thiolated laminin-derived 
loopshaped short peptide sequences (CDPVCC GTARPGYIGSRGTARCCAC), 
thiolated hyaluronan, and thiolated recombinant human collagen was obtained 
from our collaborator, Dr. Xuejun Wen and Dr. Ning Zhang (Li et al., 2013; 2014).  
This non-immunogenic hydrogel provides a structural support scaffold to the 
surrounding tissues by conforming to the irregularly-shaped lesion cavities, as it 
solidifies into a semi-solid gel with similar mechanical properties to endogenous 
CNS tissue.  At cooler temperatures, the gel remains in a liquid state, whereas, 
once it reaches body temperature it becomes semi-solid, conforming to the 
surrounding shape, thus, creating a physical continuity with the host spinal cord. 
Animal Acclimation and Gentling 
Forty adult female Sprague-Dawley rats (195-230g, Harlan, Indianapolis, 
IN) were acclimated to the housing facility, testing environments, and 
investigators (animal gentling) prior to evaluation.  However, animals were not 
placed in the TreadscanTM for familiarity, prior to baseline assessments, as 
animals perform better when untrained on the TreadscanTM (personal 
communication with Johnny Morehouse, University of Louisville).  Original n 
number (40) for statistical power analysis.  Animal housing included a 12-hour 
light and 12-hour dark cycle, air filtration system, and food and water ad libitum. 
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Figure 12.  Hydrogel Release Profiles – in vitro and 
in vivo.  (A) In vitro release profile of HGF and BDNF.  
(B) In vivo release profile of VEGF.  Dr. Xuejun Wen 
(unpublished). 
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Figure 13.  In Vivo Experimental 
Timeline.  Moderate, contusive T10 SCI in 
vivo experimental design with 
transplantation of hydrogel, VEGF, and 
GDNF, and behavioral assessments. 
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Baseline Behavior 
Forty animals were assessed for baseline motor and sensory function one 
week prior to SCI surgeries (Figure 13).  Original n number of animals per group 
was calculated in order to have a high enough statistical power analysis for 
quantification of behavior and histological measurements.  Assessments included 
the Basso Beattie and Bresnahan (BBB) open field locomotion, TreadscanTM 
(Clever Sys, Inc., Reston, VA), Gridwalk, and Hargreaves’ thermal sensitivity 
measurement (Plantar Test Analgesia Meters, Harvard Apparatus).  Each 
assessment will be explained in detail below. 
Spinal Cord Injury Surgical Procedures 
Rats were randomly assigned to receive Sham surgery (laminectomy only, 
n = 5) or T10 midline contusive SCI (n = 35).  All animals were anaesthetized 
with an intraperitoneal (IP) injection of a Ketamine (40 mg/kg)/Xylazine (5 mg/kg 
IP) mixture.  Animals were then placed on pre-warmed heating pads to maintain 
body temperature.  A midline incision was made on the dorsal surface of the skin, 
and tissue and muscle retracted until the vertebral column was reached.  Animals 
were placed in a custom vertebral stabilizer (Walker et al., 2015; Figure 15), with 
stabilization arms (Figure 15.B) affixed to the thoracic T10 vertebrae, and a 
laminectomy was performed on the T9 and T10 vertebrae, without durotomy.  
Midline thoracic contusive SCI was performed employing the Louisville Injury 
System Apparatus (LISA® device, n = 35; Figure 14), with a preset depth of 0.85 
mm.  Sham animals received laminectomy only.  Injury time, velocity, and injury 
depth were recorded from the LISA® device and analyzed to ensure there were 
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no significant differences across animals or treatment groups (Figure 16).  All 
animals received 5 mL subcutaneous injections of 0.9% saline for hydration 
following surgery.  Animals were placed in temperature controlled housing with 
moist food and water, with monitoring for recovery.  Once alert from anesthesia, 
animals were administered 0.2 mL [0.03 mg/mL] of Buprenorphine and 0.2 mL of 
[10 mg/mL] Baytril every 12 hours for the first 4 days.  Post-SCI, animals’ 
bladders were expressed manually 3 times daily, until bladder reflexes 
recovered. 
Treatment Groups Pseudo-randomization 
LISA® device SCI parameters (time, seconds; velocity, meters/second; 
and depth, millimeters) were assessed to ensure no significant differences 
existed across treatment groups.  Animals were tested behaviorally (BBB) at 3 
and 7 days post SCI, prior to transplantation surgery.  SCI rats were then 
pseudo-randomized into treatment groups based on body weight and BBB 
scores, so that all five treatment groups had a mean BBB score of 10.  Sham 
animals had a mean BBB of 21 points.  Two animals died during SCI surgeries 
and one animal died during the transplantation surgeries due to anesthetic 
effects.  Thus, after pseudo-randomization and transplantation surgeries our 
groups included: Sham (n = 5), Saline (n = 5), Hydrogel (n = 7), Hydrogel + 
VEGF (n = 6), Hydrogel + GDNF (n = 7), Hydrogel + VEGF + GDNF (n = 7). 
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Figure 14.  Louisville Impactor System Apparatus.  LISA® 
injury device and associated laptop with software. 
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Figure 15.  Surgical Stabilization Device.  (A) U-
shaped holder for surgical stabilization.  (B) Serrated 
arms for lateral vertebral stabilization. 
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Figure 16.  LISA® Injury Device Parameters.  
(A) Injury time, (B) Velocity, and (C) Injury depth. 
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Table 3.  In Vivo Experimental Design 
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Blinded Conditions 
All rats, including sham, were coded with numbers and treatment group 
information remained separated from the coded numbers throughout the study.  
Thus, all behavioral testing, SCI and transplantation surgeries, histological 
analysis, and quantification were performed under blinded conditions with animal 
treatment group information separated from the investigators. 
Transplantation Surgeries 
At twelve days following SCI, animals received transplantation of Saline (n 
= 5), Hydrogel (n = 7), Hydrogel + VEGF (n = 6), Hydrogel + GDNF (n = 7), or 
Hydrogel + VEGF + GDNF (n = 7).  Hydrogel components were mixed together 
approximately 12 hours prior to transplantation surgeries, with VEGF [15 µg/mL] 
and GDNF [5 µg/µL], or both factors added to the hydrogel within 6 hours prior to 
transplantation surgeries.  Animals were anesthetized with Isoflurane, USP 
(Piramel Healthcare, NDC 66794-013-10) administered up to effect (for each 
animal).  A midline incision was made on the dorsal surface, and tissue and 
muscle were retracted until the vertebral column was reached.  Tissue was 
cleared until the T10 a vertebra was reached, and the dural suture located 
(directly above injury epicenter).  Hydrogel with and without trophic factors was 
kept on ice prior to and during the transplantation surgeries, otherwise the 
hydrogel would become a semi-solid gel in the tube or glass pipette.  The glass 
pipettes were then loaded with saline, hydrogel, or hydrogel plus corresponding 
trophic factor.  Surgeon was kept blinded as to treatment group.  A stereotaxic 
frame was used to lower the glass pipettes to reach a depth of 0.8 mm into the 
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spinal cord.  Injections (Saline or Hydrogel) were made at injury epicenter via 
pressure injection through hand-pulled beveled glass pipettes (outer diameter 50-
70 µm).  The total volume of injection was 3 µL per rat, at approximately 1 
µL/min, 0.8 mm in depth, and occurred over duration of approximately 3 minutes, 
with a needle dwell time of approximately 5 minutes to prevent hydrogel or saline 
leakage.  Following surgery, all animals received 5 mL subcutaneous injections 
of 0.9% saline for hydration and were placed in temperature controlled housing 
with moist food and water, with monitoring for recovery.  Once alert from 
anesthesia, animals were administered 0.2 mL [0.03 mg/mL] of Buprenorphine 
and 0.2 mL of [10 mg/mL] Baytril every 12 hours for the first 4 days.  Animals’ 
bladders were expressed 2-3 times daily, until reflexes returned. 
Behavioral Assessments 
Part I: TreadscanTM Gait Analysis 
Quantitative measures of locomotor stability and coordination were 
measured using the TreadScanTM system (Beare et al., 2009).  The TreadscanTM 
apparatus consists of a motorized treadmill with translucent belt, beneath which 
angled mirrors allow a digital camera to capture the locomotion of the animals.  A 
plexiglass chamber sits above the treadmill to ensure a consistent frame of the 
animal walking for digital capture.  The accompanying TreadscanTM software 
(Clever Sys, Inc., Reston, VA) allowed us to identify animal paws, and set criteria 
for the software to recognize individual paws using captured animal footage.  
Baseline data for the TreadscanTM system was collected for each animal before 
the beginning of the experiment, along with other behavioral baseline tests.  
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Each animal was placed in the TreadscanTM chamber.  The treadmill was then 
started and the speed was gradually increased until a comfortable gait was 
reached for each animal.  Investigators then prompted the software to capture 
the animal’s gait for 2,000 consecutive frames, at 60 frames per second.  Once 
the blinded investigator was satisfied with the quality of captured locomotion, 
each video file was saved for further analysis.  Once the tester was satisfied with 
the lighting and other parameters of the setup, a background image was 
captured and calibration video recorded for the session.  A sampling of 10-15 
paw traces (per paw) were required for an acceptable ‘foot model’, which was 
built for each animal using the TreadscanTM software (Figure 17).  Upon preview, 
a video clip containing 10-15 consecutive steps was selected to be analyzed for 
each animal.  Once an acceptable foot model was built, the analysis was run 
using the input of calibration, background, animal video, and foot model.  
Appropriate gait analysis parameters were selected from previously published 
literature (Beare et al., 2009; Tom et al., 2009; Myers et al., 2012; Figley et al., 
2014; Chehrehasa et al., 2014), in addition to several other parameters only 
available in the newest versions of the software, and therefore not commonly 
used in the literature.  Testing was repeated at weeks 4 and 6 post SCI for 
animals with BBB scores above 13 (consistent plantar stepping).  Results from 6 
weeks post SCI are presented (Figures 21-22).  Statistical outliers beyond two 
standard deviations away from the mean were excluded; thus, the n number (n = 
5) is the same for all behavioral assessments. 
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Figure 17.  Treadscan™.  (A) Rat on translucent belt with 
each foot highlighted for individual foot models.  (B) Outline of 
rat with foot models, and horizontal and perpendicular body 
axes labeled.  (C) Individual foot models with body axes 
labeled.  (D)  Overview of Treadscan™ setup. 
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Figure 18.  Basso Beattie and Bresnahan 
(BBB) Open Field Locomotion.  Three 
examples of rats moving in the open field for 
BBB assessment. 
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Figure 19.  Hargreaves’ and Gridwalk tests.  (A) and (B) 
Hargreaves’ test of thermal sensitivity.  (C) Rat traversing grid 
during Gridwalk test. 
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Figure 20.  Modified Grooming Test.  (A) Rat with weight on both 
forepaws. (B) - (H) Rat grooming with only one forepaw, with body 
weight propped on the other forepaw. 
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Part II: Basso Beattie and Bresnahan Open-field Locomotion 
Animals were tested for recovery of locomotion in an open field 
environment using the Basso Beattie and Bresnahan (BBB) Locomotor Rating 
Scale (Basso, Beattie, and Bresnahan 1995, 1996).  Animals were tested at 
baseline, 3 and 7 days post SCI, and weekly for 8 weeks.  Animals’ scores from 
3 and 7 days post SCI were evaluated in order to pseudo-randomize the rodents 
into treatment groups so that all treatment groups would have a mean BBB of 10.  
Animals were tested for 4 minutes in the open field, with two blinded investigators 
scoring, and a third blinded investigator video recording each animal in each 
session (Figure 18).  Locomotion was averaged then across both rear hindlimbs, 
due to the nature of a midline contusive injury. 
Part III: Hargreaves’ Test 
Alterations in thermal sensitivity were assessed using the Hargreaves’ test 
(Plantar Test Analgesia Meters, Harvard Apparatus; Hargreaves et al., 1988; Hill 
et al., 2009).  Animals were placed in individual plexiglass boxes on top of a pre-
warmed glass surface (34oC), for 10 minutes in order to acclimate to the testing 
environment.  A thermal stimulus was then presented beneath the paw until the 
animal moved the paw in response to the stimulus, or until 20 seconds passed, 
whichever occurred first (Figure 19).  The second paw was tested, and then each 
successive animal (across 6 animals) was tested before the first paw was 
repeated.  A minimum of 3-4 minutes was maintained between trials of any paw, 
in order to allow the stimulated paw to return to a pre-stimulated level.  Animals 
were tested at baseline and week 6 post SCI.  Five trials were acquired per 
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paw/time point per animal, and three trials/paw were eventually averaged – the 
three closest paw withdrawal responses per paw. 
Part IV: Gridwalk Assessment 
Functional recovery was also evaluated using the Gridwalk test (Metz et 
al., 2000).  Animals were placed on a preconstructed grid with gaps of ~3.25cm x 
4.25cm between rungs (Figure 19).  Animals were tested for 3 minutes, by two 
investigators.  Animals were tested at baseline and weeks 6 and 8 post SCI 
(Figure 23).  Only animals with consistent plantar stepping (BBB score of 13 or 
above) were tested on the Gridwalk test. 
Part V: Modified Grooming Test for Trunk Stability 
The Grooming test was adapted for cervical spinal cord injuries (Gensel et 
al., 2006; Inoue et al., 2013), yet it was originally developed for assessing 
brachial plexus injury and recovery (Bertelli and Mira, 1993).  Once rodents feel 
comfortable with their surrounding environment, they often halt their locomotion 
or exploration and begin grooming.  Thus, it came to our attention during the 
open-field BBB locomotion and Hargreaves’ test that some rodents were able to 
support their body weight on their hindlimbs and partially rear, using both 
forepaws for grooming simultaneously, similar to Sham animals.  However, a 
portion of rats could only groom with one forepaw at one time.  These rodents 
supported their body weight on both hindlimbs and one forepaw, while grooming 
with the other forepaw (Figure 20).  The animals then shifted their body weight to 
the opposite forepaw and groomed with the second forepaw.  Animals were 
assigned a score for the ability to use both forepaws simultaneously for 
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grooming, similar to Sham, and a lessor score to grooming with only one forepaw 
at-a-time.  The observation of the rodents’ differing ability to groom was made at 
6 weeks post SCI.  Thus, the Modified Grooming test was established as a 
measure of trunk stability, and the animals were tested at week 6 post SCI 
(Figure 6). 
Transcranial Magnetic Motor Evoked Potential 
At 7 weeks post SCI, animals were restrained beneath a cloth, and 
electrodes were placed in the tibialis anterior muscle, as well as a grounding 
electrode placed in the tendon.  A magnetic wand was placed over the motor 
cortex to evoke transcranial magnetic motor evoked potentials (tcMMEPs).  
Muscle evoked potentials were recorded and traced for motor activity (Figure 27).  
All traces were assessed and background threshold ‘noise’ level (inherent within 
the signal) was defined.  Three traces per leg were averaged, and both legs were 
assessed for all rats.  Statistical outliers beyond two standard deviations away 
from the mean were excluded. 
Histopathological Analysis 
Eight weeks post SCI, tissue was collected and processed, methods 
previously described (Walker et al., 2012).  Briefly, after transcardial perfusion 
with 0.01 M Saline and 4% paraformaldehyde, the brain and spinal cords were 
dissected, and dehydrated in 30% sucrose.  Spinal cord segments 1.5 cm in 
length, surrounding the injury epicenter, were identified (Figure 28), isolated 
(Figure 29), and frozen in Tissue-Tek® O.C.T. compound (Fisher Scientific) with 
3 spinal cords per block.  Tissue was sectioned cross-sectionally at 25 μm 
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thickness on Leica CM (1860, 1950) cryostats and mounted onto Superfrost® 
glass plus slides (Fisher Scientific) in sets.  Therefore, approximately 600-800 
tissue slices were cut and mounted per animal.  Tissue was stained with cresyl 
violet acetate (Nissl) stain with eosin counterstaining and coverslip mounted with 
DPX (Fisher Scientific), for lesion area and cavity measurements.  Tissue was 
also stained using immunofluorescence for the following primary antibodies: 
mouse anti-rat endothelial cell antigen-1 (1:100; ABd Serotec MCA970F), rabbit 
anti-glial acidic fibrillary protein (GFAP, 1:200; Chemicon, AB5804), mouse 
SMI-31 (1:1000; Sigma), and mouse anti-rat ED-1 (1:200; Sigma).  The following 
secondary antibodies were used for detection: goat anti-mouse TRITC (1:100; 
Jackson Immunoresearch, 115-025-003), goat anti-rabbit FITC (1:100; Jackson 
Immunoresearch, 115-095-003), and goat anti-mouse TRITC (1:100; Jackson 
Immunoresearch, 115-025-003).  Tissue sections were coverslip mounted post 
staining using Fluoromount-G (Southern Biotech) and Hoechst 33342 (1:100; 
Invitrogen) was used for fluorescence staining of nuclei. 
Brightfield images were obtained using an Olympus BX60 microscope in 
combination with Neurolucida 9 software (MicroBrightfield, Inc.).  Based upon 
morphological appearance from the cresyl-echt violet stained tissue sections, 
lesion and spared white matter tissue was identified.  Cavity was then identified.  
Lesion, cavity, and spared white matter areas were subsequently traced from 4x  
images using ImageJ software.  Approximately 600 cord sections traced for 
brightfield quantification.   Immunofluorescent slides were imaged using a Zeiss 
Axio Imager M2 and Neurolucida 9 software (MicroBrightfield, Inc.).  RECA-1 
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positive staining was assessed morphologically for blood vessels.  Similarly, SMI-
31 positive staining was assessed for axons and GFAP positive staining was 
assessed for astrocytes.  Fluorescence integrated density (intensity/total cord 
area) was traced for regions of interest in the penumbra region of the lesion, from 
10x images and quantified using ImageJ software.  Approximately 100 cord 
sections traced for IF quantification. 
Statistical Analysis 
All quantified data are presented as the mean +/- SEM (standard error of 
the mean).  A one-way analysis of variance (ANOVA) was used to analyze: 1) 
the in vitro results of neurite outgrowth, and the in vivo portion of the study, 
including 2) BBB, 3) Treadscan™, 4) Gridwalk, 5) Hargreaves’ test, and the 6) 
Modified Grooming test, as well as the histological quantification of 7) lesion, 8) 
cavity, and 9) spared white matter area, as well as integrated fluorescence 
density for the 10) vasculature (RECA-1), 11) axons (SMI-31), and 12) astrocytes 
(GFAP).  Statistical outliers beyond two standard deviations away from the mean 
were excluded.  Only p < 0.05, data was considered significant, and the null 
hypothesis was rejected.  Tukey’s post hoc analysis was used following the one-
way ANOVA for all quantification, for pair-wise comparisons (Kao and Green, 
2008).  GraphPad Prism® was used for all statistical analyses. 
Results 
VEGF and GDNF Promote Neurite Outgrowth from Spinal Cord Neurons  
To determine whether VEGF and GDNF have any effect on neurite 
outgrowth, spinal cord neurons were treated with the two factors, alone or in 
83 
combination.  Using the ImageXpress® Micro XL, we observed and quantified 
(MetaXpress 5.1 software) significant neurite outgrowth from spinal cord neurons 
(Figure 11) in response to both VEGF and GDNF, and an additive effect when 
combined, as compared to neuronal controls (not containing any factors).  Ninety 
neurons were assessed per treatment group (Figure 9).  Treatment groups 
included: 1) neuronal controls (media and neurons), 2) VEGF 25 ng/mL, 3) VEGF 
50 ng/mL, 4) GDNF 25 ng/mL, 5) GDNF 50 ng/mL, 6) VEGF + GDNF 25ng/mL 
each, and 7) VEGF + GDNF 50 ng/mL each.  VEGF at 25ng/mL significantly 
increased total neurite outgrowth, mean process length, and mean number of 
branches, compared to neuronal (media) controls (Figure 9).  VEGF at 50 ng/mL 
significantly increased total neurite outgrowth, mean process length, maximum 
process length, and mean number of branches, compared to neuronal (media) 
controls.  While GDNF at 25 ng/mL significantly increased all four measures of 
neurite outgrowth over neuronal controls, it was not significant compared to 
VEGF at 25 ng/mL or VEGF at 50 ng/mL.  However, GDNF at 50 ng/mL 
significantly increased all measures of neurite outgrowth compared to neuronal 
controls, VEGF at 25 and 50 ng/mL and GDNF at 25 ng/mL.  VEGF 25 ng/mL + 
GDNF 25 ng/mL combined, and VEGF 50 ng/mL + GDNF 50 ng/mL combined, 
significantly increased total neurite outgrowth, mean process length, maximum 
process length, and mean number of branches compared to neuronal controls, 
VEGF at 25 and 50 ng/mL, and GDNF at 25 ng/mL.  Both VEGF + GNDF 
combination groups (25 and 50 ng/mL) appear to have additive effects on all 
measures of neurite outgrowth, compared to VEGF or GDNF alone.  However, 
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neither combination group (VEGF + GNDF) promoted statistically significant 
outgrowth more than GDNF at 50 ng/mL. 
VEGF and GDNF also resulted in a significant increase in the total number 
of neurons (Figure 10).  Thus it appears that VEGF and GDNF had 
neuroprotective effects on the neurons in culture as well as neurotrophic 
influence on neurite outgrowth.   
Treadscan™ Gait Analysis 
Hydrogel alone, Hydrogel + GDNF, and Hydrogel + VEGF + GDNF 
significantly improved (p < 0.05, ANOVA) a number of parameters of locomotion 
and coordination, as detected by the Treadscan™ (Figures 21-22).  All three of 
these treatment groups improved the following parameters: 1) Stance maximum 
area, 2) Print angle, 3) Base of support (rear track width), 4) Homologous gait 
coupling, 5) Homolateral gait coupling, 6) Diagonal coupling, 7) Brake time, 8) 
Minimum Longitudinal deviation, and 9) Maximum Longitudinal deviation, close to 
Sham levels (dotted lines in Figures 21-22).  Tukey’s post hoc analysis was run 
on statistically significant groups from the ANOVA analysis.  Thus, it appears that 
the hydrogel alone is having a structural support of the endogenous repair 
mechanism that occurs in rodents after SCI.  Similar to the in vitro results, GDNF 
appears to be the greatest contributor to functional recovery.  Additionally, none 
of these parameters are measured by the BBB, aside from print angle, which is 
qualitatively measured by BBB and quantified by the Treadscan™. 
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Parameter Description Visual description 
Stance 
Maximum 
Area 
The surface 
area occupied 
by the paw 
 
Print Angle 
The angle of 
rotation of the 
paw from the 
central body 
axis 
 
Base of 
Support 
The distance 
between the 
two rear hind-
paws 
 
Homolog-
ous Gait 
Coupling 
The coupling 
that occurs 
between the 
two front paws 
or the two rear 
paws 
 
Homolat-
eral Gait 
Coupling 
The coupling 
that occurs 
between both 
paws on the 
same side of 
the body 
 
Diagonal 
Gait 
Coupling 
The coupling 
between the 
fore-paw and 
rear-paw on the 
opposite sides 
of the body 
 
 
 
Table 4.  Treadscan™ Parameters 
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Parameter Description Visual description 
Brake Time 
The time it takes 
the paw to come 
to a halt once 
reaching the 
ground from the 
swing phase. 
 
Longitudinal 
Minimum 
Deviation 
The smallest 
deviation of the 
limbs from the 
central axis of the 
body. 
 
Longitudinal 
Maximum 
Deviation 
The largest 
deviation of the 
limbs from the 
central axis of the 
body. 
 
 
 
Table 4.  Treadscan™ Parameters (continued) 
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Figure 21.  TreadscanTM Motor Assessments at 6 Weeks Post SCI.  Hydrogel 
alone, Hydrogel + GDNF, and Hydrogel + VEGF + GDNF treatment significantly 
improved Maximum Stance Area (A), Print Angle (B), Base of Support, and (D) 
Brake time. All data was normalized to baseline, and the Sham animal data is 
represented by the horizontal dashed lines.  n = 5 per treatment group.  SEM, * = p < 
0.05, ** = p < 0.01, *** = p < 0.001. 
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Figure 22.  TreadscanTM Motor Assessments at 6 Weeks Post SCI.  Hydrogel 
alone, Hydrogel + GDNF, and Hydrogel + VEGF + GDNF treatment significantly 
improved Homologous Gait Coupling (A), Homolateral Gait Coupling (B), Diagonal 
Gait Coupling (C), Minimum Longitudinal Deviation (D), and Maximum Longitudinal 
Deviation (E) compared to Saline controls and Hydrogel + VEGF.  All data was 
normalized to baseline, and the Sham animal data is represented by the horizontal 
dashed lines. n = 5 per treatment group.  SEM, * = p < 0.05, ** = p < 0.001, *** = p < 
0.001. 
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Basso, Beattie, and Bresnahan Open-field Locomotion 
All animals (except for Sham) displayed functional deficits following injury, 
evident at 3 and 7 days post SCI (Figure 23).  Rodents have an endogenous 
spontaneous recovery following SCI, which is apparent in the Saline-treated 
animals.  Thus, all treatment groups significantly improved over the course of 8 
weeks following injury, compared to 3 days post injury.  However, no statistical 
differences were detected across treatment groups at any particular time point, p 
> 0.05 (ANOVA).  
Hargreaves’, Gridwalk, and Modified Grooming Tests 
The Hargreaves’ test did not show any significant differences across 
treatment groups at baseline or 6 weeks post SCI (Figure 24).  The paw 
withdrawal time (seconds) also did not differ significantly between baseline and 6 
weeks post SCI, p > 0.05 (ANOVA).  Thus, none of the treatments have caused 
an increased sensitivity to a thermal stimulus (hyperalgesia) in Sprague-Dawley 
rats, which is always a concern with SCI treatments and pre-clinical trials.  We 
used the Hargreaves’ test as a measure of thermal sensitivity to ensure that our 
treatments were not causing allodynia or hyperalgesia.  Allodynia is the 
perception of a noxious stimulus in response to a non-noxious stimulation.  
Hyperalgesia is the perception of a highly noxious stimulus in response to a 
mildly noxious stimulation.  It is important for preclinical studies of spinal cord 
injury to determine whether the putative treatments are causing allodynia or 
hyperalgesia, as these would be undesirable side-effects for spinal cord injured 
patients.  We could have also utilized the von Frey hair test of mechanical 
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sensitivity to measure allodynia or hyperalgesia.  However, we feel that the 
Hargreaves’ test provides us with consistent, reliable, and reproducible data to 
measure treatment-induced allodynia or hyperalgesia.  
The Gridwalk and Modified Grooming tests did not show any significant 
differences across treatments at any time points, p > 0.05 (ANOVA, Figures 25 
and 26, respectively).  The Grooming test is typically employed for cervical 
models of SCI.  However, in noticing animals pausing to groom during the 
Hargreaves’ test and BBB assessment, we modified the standard Grooming test 
and utilized it as a measure of trunk stability in our thoracic SCI model.  If further 
developed and explored as a putative measure of trunk stability, the Grooming 
test may have broader implications for detecting SCI deficit and recovery.  With 
higher n numbers, thus more statistical power for analysis, assessments such as 
Gridwalk, Modified Grooming test, and BBB might presumably show more 
significant differences across treatment groups.  However, the final n number for 
this study was n = 5 per treatment group. 
Transcranial Magnetic Motor Evoked Potential 
No significant differences were detected in tcMMEP tracings across 
treatment groups.  As locomotor activity significantly differed across treatment 
groups, there is a possibility that the tcMMEP signal was lost within the 
background ‘noise’ of the assessment.  Higher n numbers should reduce the 
variability observed across animals within and across treatment groups. 
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Figure 23.  Basso, Beattie, and Bresnahan (BBB) Motor 
Assessment.  No significant differences were observed across 
treatment groups over 8 weeks post SCI.  n = 5 per treatment group. 
SEM, p < 0.05.   
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Figure 24.  Hargreaves’ Test.  No significant differences 
were observed across treatment groups at either time point, 
and there were no significant differences between baseline 
and 6 weeks post SCI for any of the groups.  n = 5 per 
treatment group.  p > 0.05, ANOVA. 
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Figure 25.  Gridwalk Test.  No significant differences were 
observed across treatment groups at 6 weeks or 8 weeks post SCI. 
n = 5 per treatment group.  p > 0.05, ANOVA. 
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Figure 26.  Modified Grooming Test.  The grooming test 
was modified from cervical SCI models as a measure of 
trunk stability with thoracic SCI injury model.  No 
significant differences were observed across treatment 
groups.  However, this test may have broader applications 
for thoracic SCI models in the future, if further developed.  
n = 5 per treatment group.   p > 0.05, ANOVA. 
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Figure 27.  tcMMEP Recording Traces. (A) Baseline (Sham) left and right hind limbs.  
(B) Left and right hind limbs, respectively, at 7 weeks following injury.  n = 5 per 
treatment group.   
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Figure 28.  Verification 
of Injury Epicenter.  
Brains and spinal cords 
were dissected following 
perfusion, and injury 
epicenter was verified 
(yellow dotted line). 
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Figure 29.  Injury Epicenter. Case sample of injury epicenter at 
T10 (thoracic 10), 8 weeks following a moderate, midline, contusive 
SCI with the LISA device (depth of 0.85mm).  Higher magnification 
of inset, below. 
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Histopathological Analysis 
No significant differences were detectable across treatment groups for 
lesion area, cavity area, spared white matter area, or total cord area, measured 
from Cresyl-echt violet stained and imaged cross sections (Figure 31; p > 0.05, 
ANOVA).  Similarly, no significant differences were observed in astrocyte 
reactivity (GFAP), vasculature (RECA-1), or axons (SMI-31), measured by 
integrated fluorescence density across total cord area (for each parameter), p > 
0.05 (ANOVA).  However, non-significant trends were observed in reduced lesion 
cavity area at injury epicenter for Hydrogel alone, Hydrogel + VEGF, Hydrogel + 
GDNF, and Hydrogel + VEGF + GDNF (Figures 32 and 36).  Hydrogel + VEGF 
showed a non-significant trend of increased vasculature density at lesion 
epicenter, compared to Saline animals and other treatment groups (data not 
shown), and also a non-significant trend of decreased rostral-caudal cavity 
spanse (Figure 30).  Hydrogel + GDNF showed a non-significant trend of lower 
GFAP integrated density as compared to Saline and other treatment groups 
(Figure 31).  These trends are noteworthy, particularly because they might be the 
histological differences underlying the functional locomotor differences detected 
with the Treadscan™.   Higher n numbers should correspond to lower variability 
across animals in each treatment group.  Thus, with higher n numbers we would 
expect to see more parameters with statistical significance in histological 
outcomes and behavioral assessments (BBB, Gridwalk, Modified Grooming test), 
similar to the differences detected with the Treadscan™ in this study. 
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The SCI resulted in an immune response (Figures 37 and 39), an attempt 
by microglial cells to clear tissue debris.  However, no significant increase in 
immune response (ED-1) was observed across treatment groups (quantified data 
not shown).  Thus, hydrogel did not provoke a significant immune response.  This 
was expected as the hydrogel is designed to be non-immunogenic.  Individual 
microglia (red) and reactive astrocytes (green) can be visualized by 
immunofluorescence histopathology in Figure 39.  Immunofluorescence 
integrated densities of RECA-1 (vasculature), GFAP (astrocytes), and SMI-31 
(axons) were compared across treatment groups (Figure 31).  Higher power 
immunofluorescence images reveal the overlap of the vasculature (RECA-1) and 
glial endfeet (GFAP) that are part of the neurovascular unit (Figures 33, 34, 38, 
and 42).  The vascular basement membrane (laminin) is visualized in Figure 35 
along with RECA-1.  Higher power images of the vasculature (RECA-1) reveal 
individual red blood cells (Figures 40 and 41). 
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Figure 30.  Rostral-Caudal Cavity Spanse.  The spanse of cavity 
extending rostrally and caudally was measured.  No significant 
difference exists across treatments groups, although Hydrogel, 
Hydrogel + VEGF, and the combined group of Hydrogel + VEGF + 
GDNF showed trends of less cavity compared to Saline and 
Hydrogel + GDNF groups.  n = 5 per treatment group.   
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Figure 31.  Histopathology.  (A) Cresyl-echt violet staining of cross-sections.  (B) 
RECA-1 staining for the vasculature (top row).  GFAP staining for astrocytes (middle 
row).  SMI-31 staining for axons (bottom row).  No statistical significance was 
observed from histopathological results (data not shown).  Image magnification for 
brightfield images is 4x, and for immunofluorescence is 10x magnification was used. 
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Figure 32.  Epicenter Lesion Cavity Area.  A non-significant trend of 
reduced lesion cavity area (µm2) was observed for all treatment groups 
containing Hydrogel.  Sham tissue was uninjured and displayed no cavity.  
n = 5 per treatment group.  p > 0.05. 
 
103 
  
Figure 33.  RECA-1 & GFAP 
Immunofluorescence Staining.  
(A) GFAP (green) for astrocytes, 
(B) RECA-1 (red) for vasculature, 
and (C) merged image with 
Hoechst included for cell nuclei 
(blue).  
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Figure 34.    RECA-1 & GFAP 
Immunofluorescence Staining.  
(A) GFAP (green) for astrocytes, 
(B) RECA-1 (red) for vasculature, 
and (C) merged image. 
105 
 
Figure 35.  RECA-1 & Laminin 
Immunofluorescence Staining.  
RECA-1 (red) for vasculature, (A) 
and (B).  Laminin (green,C).  
Merged image (D). 
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Figure 36.  Epicenter Lesion and Spared 
White Matter.  (A) Lesion Area at epicenter.  
(B) Spared white matter area at epicenter.  
Neither parameter is statistically significant.  
n = 5 per treatment group.  p > 0.05. 
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Figure 37.  Hydrogel Animal Immunofluorescence Staining.  GFAP (green) 
highlights the reactive astrocytes.  RECA-1 (red) displays the vasculature.  
Hoechst (blue) marks the cell nuclei.  Some blood vessel fragments have likely 
been phagocytized by microglial cells, with a more globular shape appearance and 
highlighted in red, within the lesion epicenter.  Tissue taken several mm rostral 
from injury epicenter.  
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Figure 38.  Hydrogel + VEGF + GDNF Immunofluorescence Staining.  GFAP 
(green) highlights the reactive astrocytes.  RECA-1 (red) displays the vasculature.  
Hoechst (blue) marks the cell nuclei.  Tissue taken ~3mm rostral to injury 
epicenter.  (A) A small amount of lesion can be seen in the dorsal white matter of 
the cord.  Several areas of vasculature are highlighted below with corresponding 
boxes (B and C) above.  (B)  Astrocytic endfeet are visible on several blood 
vessels. 
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Figure 39.  Immunofluorescence Staining.  GFAP (green) highlights the reactive 
astrocytes.  OX42 (red) labels microglia.  Hoechst (blue) marks the cell nuclei.  (A) 
Dorsal white matter injury visible with microglia (red) and reactive astrocytes 
(green).  (B) Central canal region with many individual astrocytes visible (green).  
(C) Reactive astrocytes (green) and microglia (red).  
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Figure 40.  Vascular Immunofluorescence Staining.    (A) 10x image of entire 
spinal cord several mm from injury epicenter.  At 40x (B) and 100x (C) individual 
red blood cells were visualized within spinal cord grey matter vasculature.  
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Figure 41.  Vasculature and Glial Scar Immunofluorescence Staining.    
Hydrogel cord at injury epicenter.  Red blood cells can be visualized in the blood 
vessel highlighted with the yellow (dotted) box.  
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Figure 42.  Vasculature and Glial Endfeet Immunofluorescence 
Staining.    (A) RECA-1 (red) staining for blood vessels.  (B) GFAP 
(blue) staining for reactive astrocytes.  (C) Merged image of RECA-
1 and GFAP, showing astrocytic endfeet as well as intertwining of 
astrocytes with the vasculature.  
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Figure 43.  Cresyl-echt Violet Staining.    Representative images of 
epicenter tissue show grey and white matter sparing.  Higher 
magnification shows more white matter sparing in the dorsal columns 
of the Hydrogel, Hydrogel + GDNF, and Hydrogel + VEGF + GDNF 
treatment groups as compared to the Saline and Hydrogel + VEGF 
groups.  This may account for the significant locomotor recovery of 
these three groups, as observed by the Treadscan™ assessment. 
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Discussion 
While GDNF is a well characterized neurotrophic factor, VEGF’s influence 
on the nervous system has been primarily recognized over the past two decades.  
VEGF and GDNF have been shown to synergize at the cRET receptor (Tufro et 
al., 2007) in vitro, and to have synergistic neuroprotective benefits in other in vivo 
studies, such as ALS (Krakora et al., 2013) and Parkinson’s disease (Herran et 
al., 2013).  Moreover, the combination of VEGF and GDNF has also been shown 
to delay disease onset, increase survival period, significantly maintain motor 
function (BBB), and provide motor neuron protection (Lambrechts et al., 2003; 
Azzouz et al., 2004; Storkebaum et al., 2005; Krakora et al., 2013).   A thorough 
review of the literature provided us with background for in vitro and in vivo 
concentrations of VEGF and GDNF. 
In the present study, the first objective was to assess the neurite 
outgrowth in response to VEGF and GDNF, specifically of spinal cord neurons.  
The findings suggest that VEGF and GDNF both promote neurite outgrowth and 
have an additive effect when combined.  This effect appears to be largely driven 
by GDNF for all measures of neurite outgrowth, as GDNF [50 ng/mL] showed 
significantly greater total neurite outgrowth, mean process length, maximum 
process length, and mean number of branches than GDNF [25 ng/mL], VEGF [25 
ng/mL], VEGF [50 ng/mL], and neuronal controls.  Whereas, the outgrowth and 
branching promoted by GDNF [50 ng/mL] did not significantly differ from either of 
the combined VEGF + GDNF groups, indicating that GDNF likely contributed the 
most to the effects in the combination group. 
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In SCI animal models, GDNF has been shown to promote significant 
neurite and axonal growth (Iannotti et al., 2003; Blesch and Tuszynski, 2003; 
Dolbeare and Houle, 2003), and increased neurite branching (Deng et al, 2016).  
Additionally, in vivo GDNF has been shown to reduce astrogliosis (Deng et al., 
2013; Ansorena et al., 2013), increase myelination (Zhang et al., 2009; Deng et 
al., 2013), increase intralesional vasculature (Zhang et al., 2009; Ansorena et al., 
2013), and improve functional recovery (Cheng et al., 2002; Kao et al., 2008; 
Deng et al., 2013; Ansorena et al., 2013).  Thus, it was expected that the 
combination of VEGF and GDNF (slowly released from hydrogel) would create a 
favorable environment, in vivo, for tissue repair and improved functional 
recovery.  We anticipated that the hydrogel would serve as both a structural 
matrix to fill the contusion injury-induced cavitation and a functional reservoir to 
protect the VEGF and GDNF proteins from degradation by the surrounding toxic 
lesion milieu, and slowly release those over the course of approximately four 
weeks post transplantation. 
Significant functional recovery was observed with Hydrogel alone, 
Hydrogel + GDNF, and Hydrogel + VEGF + GDNF groups using the TreadscanTM 
system, whereas the BBB, Gridwalk, and Modified Grooming test did not detect 
significant differences across treatment groups.  First, we note that Hydrogel 
alone significantly improved locomotor outcomes as measured by the 
TreadscanTM.  Thus, the Hydrogel itself had a positive effect on locomotion.  
Similarly, a hyaluronan and methylcellulose based-hydrogel delivered 
intrathecally resulted in reduced inflammatory cytokines, a reduction in the glial 
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scar deposition (CSPGs), reduced lesion volume, improved axonal conduction, 
and improved motor function (Austin et al., 2012).  Other studies utilizing a 
bioengineered tissue as the sole treatment after SCI have revealed beneficial 
axonal and astrocytic growth into the lesion (Marchand and Woerly, 1990; 
Marchand et al., 1993).  Similarly, in a T9 transection injury model, significant 
axonal regrowth was observed in response to transplanted thiolated hyaluronic 
acid hydrogels (Horn et al., 2007).  A study employing a Neurogel™ treatment 
after SCI resulted in significant axonal growth, angiogenic vascular growth, and 
astrocyte process growth into the hydrogel implant, along with significant 
improvements in motor function (Woerly et al., 2001a), which were enhanced by 
enriched housing environments.  The non-significant trend of increased spared 
white matter in the Hydrogel, Hydrogel + GDNF, and Hydrogel + VEGF + GDNF 
groups (Figure 36) is evident in examination of the dorsal columns of the spinal 
cord (Figure 43), as well as greater spared grey matter for these three groups.   
Second, in considering the significant recovery observed using the 
TreadscanTM system, one possible explanation for no significant differences in 
other behavioral measurements is that the final n number in each group might 
not be high enough to tease apart minor differences in the other behavioral 
measures.  Another possible explanation is that the TreadscanTM has the 
capability to measure some parameters of locomotion that BBB assessment 
does not.  For example, TreadscanTM and CatwalkTM can measure footprint area, 
pressure maps, stride length, stride width (base of support), gait parameters 
(swing time and break time), and more detailed measures of coordination.  Figley 
121 
et al. (2014) observed significant improvement after treatment with a 
bioengineered zinc-finger VEGF-A using the CatwalkTM, although no differences 
were observed through BBB assessments.  Additionally, the TreadscanTM 
reduces inter-rater variability and investigator bias, even for blinded studies, 
particularly on the most subjective measures (toe clearance and coordination).  
Taken together, these indicate the usefulness in supplementing the BBB 
assessment with other motor assessments following SCI, such as the 
TreadscanTM, CatwalkTM, or Footprint.  A combination of behavioral assessments 
provides the most thorough and in-depth knowledge of functional deficits and 
recovery (BBB, TreadscanTM, CatwalkTM, Footprint, Gridwalk, Grooming). 
For example, in this study we adapted the grooming test and used it as a 
measure of trunk stability.  We observed the animals stopping to groom during 
the BBB and Hargreaves’ tests (Harvard Apparatus), whenever they felt 
comfortable in their surroundings.  It was obvious that some rodents could groom 
using both forepaws simultaneously, like Sham animals, while others could only 
groom with one forepaw at-a-time and required the second forepaw to be on the 
ground supporting the rodent’s body weight. We observed an interesting non- 
significant trend, which supports the idea that this modified grooming test might 
be a useful measurement for trunk stability after SCI, when used in conjunction 
with the BBB, TreadscanTM or CatwalkTM, and Gridwalk. 
Some SCI treatments have been shown to provoke increased sensitivity to 
thermal or mechanical stimuli.  We feel that the Hargreaves’ test provides us with 
consistent, reliable, and reproducible data to measure treatment-induced 
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hyperalgesia.  Thus, we employed the Hargreaves’ test in this study, and no 
significant differences were observed across time or across treatment groups.  
This has important clinical implications because putative therapeutic approaches 
which do increase sensitivity to thermal stimuli, thus corresponding to 
hyperalgesia, do not progress on to clinical trials. 
VEGF significantly promoted neurite outgrowth in vitro, but failed to 
promote significant improvements in vivo.  Here we discuss some important 
considerations of factors that might contribute to these observed differences.  
First, in vitro and in vivo conditions require different concentrations of factors, as 
the surrounding cells, tissue, and connected organs of the body influence the 
exposure of the host tissue to the transplanted trophic factors.  Whereas, in the in 
vitro experiment, the neurons were directly exposed to the trophic factors with 
less than 5% other cells types in the culture competing for trophic factor access. 
Second, the in vitro study did not include hydrogel, thus the neurons had 
immediate, direct exposure to VEGF and GDNF concentrations, whereas, in vivo 
the hydrogel protected the proteins from degradation and had a time-controlled 
release profile of approximately four weeks.  The in vitro study could be 
conducted again in the future, with hydrogel (mixed with VEGF and GDNF) 
added to the neuronal cultures.  However, this experiment was not performed in 
this study.  If hydrogel embedded with VEGF and GDNF were added to the 
previously plated neuron cultures, we might expect to see a slower neurite 
outgrowth compared to the current study which did not include the hydrogel.  We 
would anticipate possibly seeing greater outgrowth from the hydrogel + GDNF + 
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VEGF or hydrogel containing either factor alone, as compared to media controls, 
but likely only if neurite outgrowth were observed for longer periods of time than 
the current study, due to the fact that the hydrogel withholds the trophic factors, 
thus it takes longer time before the neurons are exposed to all of the factors. 
In contrast, if the neurons had been mixed with hydrogel before plating, 
and then the trophic factors were added directly to the hydrogel neuronal co-
culture, then we would expect to see greater outgrowth of the neurites compared 
to our current study, without hydrogel, before any factors were added.  However, 
hydrogel and neuronal cultures with subsequent addition of trophic factors should 
yield greater outgrowth than hydrogel and neuronal cultures with only media 
added.  Similar to the previously described future study, in order to see this 
outgrowth from the hydrogel and neuronal cultures, it will likely take longer for the 
trophic factors to reach all of the neurons, as the factors must diffuse across the 
hydrogel.  Thus, to observe the increased outgrowth, the plates might need to be 
assessed at time points longer than 5 days, perhaps on the order of 10-14 days 
in culture.  This proposed study of mixing hydrogel with neurons, plating them, 
and then adding the trophic factors would be a good simulation model for an in 
vivo study in which cells (Schwann cells, mesenchymal stromal cells, 
oligodendrocyte precursors, neural progenitors, endothelial cells) are embedded 
within the hydrogel, trophic factors are mixed with the hydrogel, and this 
combination is transplanted into the injured spinal cord. 
Third, the in vitro study was performed on embryonic day 15 (E15) 
isolated spinal cord neurons and the in vivo study was performed on adult 
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Sprague Dawley rats.  Thus, the axonal growth response on adult neurons in 
vivo might not be as robust as the outgrowth observed from younger neurons in 
vitro.  Fourth, it is important to recall that VEGF’s neurite outgrowth effects (in 
vitro) were modest, thus, possibly not sufficient enough in vivo to promote 
significant improvements in functional recovery or histopathology.  Fifth, the in 
vivo study included a transplantation time point of 12 days post SCI.  Therefore, 
this leads us to another important consideration – the optimal in vivo 
transplantation time point might differ between VEGF and GDNF.  Perhaps the 
transplantation time point needs to be further optimized, and determined if the 
optimal time point for VEGF and GDNF differ.  Twelve days post SCI is a 
subacute treatment as it is just at the end of the acute phase following injury.  
VEGF given too early in the acute phase, following SCI has been shown to be 
detrimental (Benton and Whittemore, 2003).  If the optimal time point for 
transplantation does differ between VEGF and GDNF, then two different time 
points can be achieved through one transplantation of hydrogel containing both 
factors by embedding one factor (most likely VEGF) into nanoparticles and then 
embed those nanoparticles into hydrogel containing GDNF.  Thus, the GDNF will 
have a release profile that begins sooner than the VEGF.  Therefore, the 
hydrogel can actually be transplanted as early as 7-8 days post SCI, when a 
cavity has formed.  Thus, there is a space to hold the hydrogel. 
Another consideration is that VEGF might need to be in combination with 
other factors in order to have in vivo efficacy at promoting significant 
histopathological or functional outcomes, as indicated by two combinational SCI 
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papers administering VEGF and PDGF (Lutton et al., 2011, Chehrehasa et al., 
2014), and possibly by the in vivo Hydrogel + VEGF data from this study.  In the 
first of these two cited studies (hemisection SCI model), VEGF and PDGF were 
only beneficial when administered in combination (Lutton et al., 2011).  Similarly, 
in the second study (contusion SCI model), either factor alone resulted in 
behavioral results similar to control animals (BBB of 10), whereas VEGF and 
PDGF in combination resulted in significantly improved locomotion (BBB of 18) 
and significantly reduced lesion cavity (Chehrehasa et al., 2014).  One argument 
is that VEGF causes permeability of the vasculature and too much permeability 
can lead to extravasation of inflammatory mediators, likely exacerbating the 
lesion environment (Benton and Whittemore, 2003).  However, it is noteworthy 
that in this study there was no evidence of an exacerbated inflammatory 
response (as assessed with ED-1) with any treatment groups, as compared to 
Saline treated animals or Sham controls.  Thus, we do not believe any of our 
treatments caused a more permeable blood-spinal cord barrier, above and 
beyond the initial mechanical injury and the endogenous secondary wave of 
injury effects on the intactness of this barrier. 
Lutton and colleagues (2011) suggest that the addition of PDGF and 
VEGF as a combinational therapy stabilizes angiogenic vasculature and forms an 
intact blood-spinal cord barrier, necessary for correct maintenance of fluids and 
molecules inside the blood circulation and inside the surrounding tissues.  Thus 
another potential combinational treatment approach would be to include VEGF, 
GDNF, and PDGF inside the hydrogel.  However, the caveat is that the optimal 
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transplantation time point for each of the factors might not be the same, which 
necessitates a time course study to identify the optimal transplantation time 
points.  Once identified, the time course for each factor could then be achieved 
by embedding the factor to be released last (presumably PDGF) in nanoparticles 
designed with layers and concentrations that allow it to have the slowest release.  
These nanoparticles could then be embedded into hydrogel containing other 
nanospheres which have a different biodegradable profile thus that their contents 
(presumably VEGF) would be released slightly before the PDGF nanoparticles.  
Then, contained within the hydrogel itself, could be the third factor (likely GDNF) 
that would be released at the earliest time point.  Thus, instead of transplanting 
at 12 days post SCI, this combinational hydrogel could be transplanted as early 
as 7-8 days post SCI.  This would afford an earliest release of GDNF, followed by 
VEGF with a final release of PDGF.  Thus, GDNF’s neuroprotective benefits 
could begin during the acute phase of SCI, with VEGF’s influence on the neurons 
and vasculature would not begin too early during the peak of the inflammatory 
phase (leaky/disrupted blood vessels), and the final release would be the PDGF, 
to stabilize the angiogenic vasculature and stem cell proliferation.  
Conclusions 
In summary, VEGF and GDNF promoted significant neurite outgrowth and 
branching from embryonic spinal cord neurons in vitro.  Furthermore, the 
combination of VEGF and GDNF provoked an additive response of neurite 
outgrowth and branching, as anticipated based on in vivo literature of ALS and 
Parkinson’s disease models (Krakora et al., 2013; Herran et al., 2013).  
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Additionally, in vitro results matched in vivo results – treatment groups containing 
GDNF showed the most neurite outgrowth from spinal cord neurons while animal 
treatment groups containing GDNF resulted in the greatest improvement in 
functional recovery. 
The in vivo Treadscan™ parameters revealed that hydrogel alone 
improved functional recovery as much as hydrogel + GDNF, and hydrogel + 
VEGF + GDNF.  Therefore, the in vivo data supports the idea that hydrogel’s role 
as a structural scaffold, for growing vasculature, axons, and astrocytic processes, 
is just as important as its functional purpose of slowly releasing trophic factors 
while protecting them from degradation.  Moreover, due to its non-immunogenic 
and its in-situ gelable properties, the hydrogel has the capability of conforming to 
the non-uniform lesion cavity of each individual host without provoking an 
immune response.  This, along with the fact that no increased sensitivity to a 
thermal stimulus was observed, supports the further exploration of this hydrogel 
for future therapeutic use for repairing the injured spinal cord.  Thus, future 
studies employing hydrogel will likely include various trophic factor combinations, 
some possibly embedded within nanoparticles prior to embedding within the 
hydrogel itself, to allow for various time-controlled release profiles of the different 
trophic factors.  Designing bioengineered matrices to promote growth guidance 
and directionality is also an important consideration for future studies.   
Combinations of transplanted cells, trophic factors, and enzymes – all embedded 
within bioengineered matrices to protect and slowly release the factors, cells, and 
enzymes – also appear to be promising therapeutic approaches. 
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OVERALL DISCUSSION 
SCI is a devastating and disabling condition and yet, currently no 
effective treatments exist.  Neurosurgeons, neuroscientists, and 
neurotraumatologists have been working for over 5,000 years to find an 
effective treatment.  However, it was not until the twentieth century that 
neuroscientists first started seeing breakthroughs in reaching the goals set by 
Santiago Ramon y Cajal when he encouraged future neuroscientists to try to 
change the ‘irreversibility’ of the central nervous system (Schwab and Bartholdi, 
1996). 
Angiogenesis following SCI 
Despite the toxic lesion environment at injury epicenter after SCI, an 
endogenous angiogenic response occurs, peaking between 7-14 days post-
injury, but regressing coincident with the onset of cavitation, in both rats and 
higher primates (Loy et al., 2002; Casella et al., 2002; Benton et al., 2008a; 
Fassbender et al., 2011).  We therefore, hypothesized that the angiogenic 
vasculature regresses due to a loss of structural support, with the onset of cystic 
cavitation.  Therefore, the overall goal of this dissertation research was to provide 
a structural scaffold for vascular reorganization, axonal regrowth, and tissue 
repair following contusive SCI, by employing a novel bioengineered hydrogel. 
Bioengineered Tissues for SCI Treatment 
Bioengineered matrices have been employed for treatment for SCI since 
the early 1990’s (Marchand and Woerly, 1990).  The next few years saw major 
advancements in optimizing the bioengineered tissues for the structural and 
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functional properties.  The ultimate goal is axonal regrowth through-and-beyond 
the distal end of the lesion, for functional reconnections of axons with their target 
neurons, and ultimately for improved functional recovery.  Thus, providing 
directionality to the bioengineered tissue is worthwhile, and might be useful for 
future approaches with our bioengineered hydrogel.  This is necessary in order to 
create a full connection of neuronal activity from the brain down through the 
spinal cord, to the neurons that connect to the muscles in our limbs and our 
internal organs, for movement and to sustain life (heartbeat, respiration, 
digestion, bladder function). 
Overlapping Signals in Nervous and Vascular Systems 
Andreas Vesalius gave us clues to the overlapping development of the 
vascular and nervous systems in his 1543 publication (De humani corporis 
fabrica, On the fabric of the human body, 1543) as noted by Carmeliet and 
Tessier-Lavigne (2005).  Dr. Peter Carmeliet and colleagues have been 
instrumental in linking the vascular and nervous systems and the overlapping 
signaling between the two, as well as overlapping signaling to other various cell 
types (Carmeliet and Storkebaum, 2002; Storkebaum et al., 2004a; Storkebaum 
and Carmeliet, 2004b; Zacchigna et al., 2008; Ruiz de Almodovar et al., 2009; 
Carmeliet and Ruiz de Almodovar, 2013).  Additionally, other publications also 
encouraged us to employ VEGF and GDNF embedded within bioengineered 
hydrogel for treatment of traumatic SCI.  Publications showing the angiogenic 
vasculature regresses with the onset of cystic cavitation (Loy et al., 2002; 
Casella et al., 2002; Benton et al., 2008a; Fassbender et al., 2011) prompted us 
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to utilize our hydrogel to rescue this endogenous angiogenic response by 
providing a structural support matrix for the angiogenic vasculature.  Studies 
showing deletions in the VEGF promoter region result in neurodegenerative 
phenotypes in mice, similar to ALS, and showing VEGF is important for 
maintenance of motor function (Oosthuyse et al., 2001) also prompted us to 
hypothesize that the VEGF will positively influence the CNS tissue repair, 
provide neuroprotection to neurons, if the treatment is applied at an early 
enough time point post-injury.  Furthermore, intact vasculature is crucial for 
delivering oxygen and nutrients and for removing toxic wastes from the tissues.  
Therefore, we hypothesized that delivering VEGF to the lesion epicenter via a 
bioengineered hydrogel might positively influence the endogenous angiogenic 
response while promoting neuron survival and growth, Schwann cell migration 
and survival, and influencing microglia and astrocytes due to the pleiotropic 
mechanisms of VEGF (Storkebaum et al., 2004a). 
VEGF and GDNF Combinational Treatment Approach 
Tufro et al. (2007) encouraged us to use GDNF in combination with 
VEGF, as both have been shown to synergize at the cRET receptor.  
Additionally, VEGF and GDNF significantly promoted animal survival, delayed 
disease onset, and maintained motor function in an ALS neurodegenerative 
disease model (Krakora et al., 2013).  Likewise, in a 2013 Parkinson’s disease 
model (Herran et al.) VEGF and GDNF had an additive effect on neuron survival 
and increased axon fiber density compared to control animals or animals 
receiving VEGF or GDNF alone. 
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GDNF Treatment for SCI Repair 
Additionally, SCI literature has shown GDNF promotion of neuroprotection 
(Arce et al., 1998; Soler et al., 1999; Nicole et al., 2001), increased intralesional 
vasculature (Zhang et al., 2009; Ansorena et al., 2013), enhanced axonal growth 
(Blesch and Tuszynski, 2001; Dolbeare and Houle, 2003), reduced astrogliosis 
(Iannotti et al., 2003; Deng et al., 2011a; Ansorena et al., 2013), increased 
myelination (Zhang et al., 2009; Deng et al., 2013), and improved functional 
recovery (Cheng et al., 2002; Kao et al., 2008; Deng et al., 2013; Ansorena et al., 
2013).  In a Parkinson’s disease model, Iravani et al. (2012) observed 
neuroprotection following GDNF administration.  Furthermore, in a Huntington’s 
disease model, neural stem cells secreting GDNF conferred striatal 
neuroprotection, showing the advantage of a combinational treatment approach 
(Pineda et al., 2007).  Moreover, in another Huntington’s disease model GDNF 
delivered via an adeno-associated viral vector into the striatum, provided 
neuroprotection to both nitric oxide synthase striatal interneurons as well as 
parvalbumin striatal interneurons (Kells et al., 2004).  Following SCI, Zhang et al. 
(2009) showed that GDNF administration increased the number of myelinated 
axons and the number of blood vessels. 
Combinational Treatment Approaches for SCI 
Based on current literature within the SCI field, combinational treatment 
approaches appear to hold the greatest therapeutic potential (Xu et al., 1995; 
Guest et al., 1997; Sayer et al., 2002; Fouad et al., 2005; Lutton et al., 2011; Lu 
et al., 2012; Deng et al., 2013; Ansorena et al., 2013; Zhang et al., 2013).  
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Collectively, these studies highlight the importance of combinational treatment 
approaches and the beneficial effects of VEGF and GDNF for repairing the 
injured spinal cord.  Therefore, we utilized a combinational treatment approach 
employing a novel, non-immunogenic bioengineered hydrogel embedded with 
VEGF and GDNF following a moderate midline T10 contusion SCI. 
VEGF and GDNF Promote Significant Neurite Outgrowth 
In vitro, we observed significant neurite outgrowth in response to VEGF 
and GDNF, with a possible additive effect from the combination of both factors.  
VEGF and GDNF also resulted in a significant increase in the mean number of 
neurite branches, the maximum neurite length, the mean neurite length, and the 
total number of neurons.  Thus it appears that VEGF and GDNF had 
neuroprotective effects on the neurons in culture as well as neurotrophic 
influence on neurite outgrowth.  These results correspond well to findings from 
the literature on both VEGF and GDNF for neuroprotection and neurotrophic 
support.  The data supports the idea that GDNF is having a stronger influence on 
the neurons than the VEGF.  It is important to keep in mind that hydrogel was not 
mixed with the neurons and trophic factors in vitro.  However, adding the 
hydrogel in with the cultured neurons and trophic factors is a good future 
direction. 
Improved Locomotion with Various Hydrogel Treatment Groups 
Similar results were observed in vivo as in vitro, with groups containing 
GDNF having greater influence on restoring locomotion than VEGF.  Hydrogel, 
Hydrogel + GDNF, and Hydrogel + VEGF + GDNF groups all showed Sham-like 
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locomotion in the following Treadscan™ parameters: 1) Stance maximum area, 
2) Print angle, 3) Base of support, 4) Brake time, 5) Homologous gait coupling, 6) 
Homolateral Gait coupling, 7) Diagonal gait coupling, 8) Longitudinal maximum 
deviation, and 9) Longitudinal minimum deviation.  In other words, the area on 
the ground for which the paw occupied (stance maximum area) was significantly 
improved with Hydrogel, Hydrogel + GDNF, and Hydrogel + VEGF + GDNF 
treatment.  Oftentimes, after SCI, the paws can have an altered footprint, 
typically a smaller footprint due to injury and the angle in which the paw makes 
contact with the ground due to the injured limb.  The angle of the paw from the 
central body axis (print angle) was significantly improved with the same three 
treatment groups as well.  Internal and external paw rotation is quite common 
after SCI, and is a major component of the BBB assessment.  The distance 
between the rear hind limbs (base of support) was also similar to sham animals, 
for the same three treatment groups (Hydrogel, Hydrogel + GNDF, and Hydrogel 
+ VEGF + GDNF).  The base of support can be thought of similar to a person 
learning to roller blade – the wider the stance the less stable, the narrower the 
stance the more stable.  Thus, after SCI, rodents typically have a wider base of 
support which begins to narrow and return closer to baseline (sham) levels with 
treatment or recovery.  The amount of time it takes the animal to stop the paw 
from motion once it touches the surface of the ground (brake time) was also 
similar to sham levels for Hydrogel, Hydrogel + GNDF, and Hydrogel + VEGF + 
GDNF groups.  This again shows more stability in open field locomotion.   The 
coupling between the front set of paws or rear set of paws (homologous gait 
134 
coupling), the coupling between the right front and rear paw as well as the 
coupling between the left front and rear paw (homolateral gait coupling), and the 
coupling between the opposite limbs – front right and rear left as well as front left 
and rear right (diagonal gait coupling) were returned to sham levels for the 
Hydrogel, Hydrogel + GNDF, and Hydrogel + VEGF + GDNF treatment groups.  
The minimum and maximum distance of the paws from the central body axes 
(longitudinal minimum deviation and longitudinal maximum deviation, 
respectively), were also similar to sham animals for the same three treatment 
groups.  Again, this shows that Hydrogel, Hydrogel + GNDF, and Hydrogel + 
VEGF + GDNF treatment groups significantly improved locomotor function, as 
detected by the Treadscan™ system.  These in vivo results are similar to the in 
vitro findings from the study, in which GDNF played a more significant role in 
neurite outgrowth than VEGF, particularly at higher doses. 
Putative Limitations of the Study 
We can only speculate that the small n number of the study, variability 
across animals, and the subjective nature of some of the BBB assessments 
resulted in no significant findings from the BBB assessments.  Additionally, it is 
notable that the significant parameters in this study, as measured by the 
Treadscan™, aside from print angle (paw rotation), are not measurements in the 
BBB.  Paw rotation, as measured by the BBB is a qualitative assessment – 
internal or external – while the Treadscan™ provides a quantitative 
measurement of paw rotation (in degrees) from the central body axes.  Thus, this 
study emphasizes the importance of multiple motor and sensory assessments 
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following SCI.  Batteries of tests provide the most comprehensive picture of 
functional deficits as well as recovery and treatment effects.  Therefore, we feel it 
is quite useful to employ the Treadscan™, Catwalk, or Footprint measures in 
addition to the BBB, along with other motor and sensory assessments, such as 
the Hargreaves’ test, von Frey test, Gridwalk, sticker removal test, and Grooming 
test. 
Suggested Future Directions 
Further study is needed in order to tease apart why the Hydrogel + VEGF 
did not confer as much functional recovery as the Hydrogel only group.  It is 
possible that the optimal transplantation time point for VEGF is not at 2 weeks 
post injury.  The GDNF might be having such a large effect on functional 
improvement that it had a greater influence on the Hydrogel + VEGF + GDNF 
group, in order for functional improvement to be significant in this group as well.  
This hypothesis matches the in vitro results, in which GDNF played a greater role 
than the VEGF.  However, our in vivo study contained an additional variable 
(hydrogel), thus a direct comparison cannot be made. 
Therefore, in order to further evaluate the factors influencing the in vivo 
study, a larger n number is necessary.  A larger n number would provide higher 
statistical power for analysis, and might tease apart minor differences in the BBB 
assessment. 
Further development of the modified Grooming test might also show 
promise for this assessment for future SCI studies using thoracic contusion injury 
models.  The Grooming test is already well-established for cervical SCI models, 
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but appears to hold great promise for use with thoracic SCI models as well, if 
further developed and explored.  
One method to strengthen the current study would be to verify the 
biological activity of the VEGF and GDNF at various time points from in vivo 
tissue.  Doing an enzyme-linked immunosorbent assay (ELISA) would detect the 
presence of two trophic factors at various time points post-injection.  However, it 
does reveal the biological activity of the trophic factors.  Thus, to attempt to 
determine the biological activity of the transplanted trophic factors, a section of 
spinal cord tissue (including injury epicenter) would be extracted at various time 
points post-hydrogel transplantation.  The tissue segment would be sonicated 
and ground up, and exposed to cultured embryonic spinal cord neurons, similar 
to our in vitro study (previously described).  If greater neurite outgrowth is 
observed in the VEGF, GDNF, and VEGF + GDNF treated animals compared to 
Saline controls then it is likely that the VEGF and GDNF are still biologically 
active at that time point.  A caveat is that the neurite outgrowth might be a direct 
outcome of VEGF and GDNF on neurons or an indirect outcome through VEGF 
and GDNF influence on other cell types.  For instance, VEGF promotion of 
angiogenic vasculature – creating a more favorable environment for neuron 
survival; VEGF and GDNF recruitment of glial cells (Schwann cells) to the lesion 
area – to aid in tissue repair and remyelination; VEGF promotion of migration and 
proliferation of microglia – to clean up the dead cellular debris; oligodendrocytes, 
VEGF promotion of astrocyte proliferation – to contain the toxic lesion 
environment; GDNF positive modulation of the astrocytic glial scar – to 
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encourage intermingling between neuron and astrocytic processes.  Additionally, 
the cellular debris and toxic lesion environment from the ground tissue graft 
might cause neuron apoptosis within the neuronal culture. 
Another way to approach this question is to incubate hydrogel with 
embedded VEGF, GDNF, or both at 37oC (body temperature) for varying time 
points, for instance 1-4 weeks.  Then, at 5 days, 7 days, 2 weeks, 3 weeks, and 4 
weeks take the hydrogel out of the incubator and add to the cultured spinal cord 
neurons.  Next, assess neurite outgrowth, to determine if the VEGF and GDNF 
have an even greater neurite outgrowth than the hydrogel only control group or 
the media only neuronal control group.  This does not exactly simulate in vivo 
conditions, but would be a way to assess biological activity of the VEGF and 
GDNF at various time points post-incubation in hydrogel, at simulated body 
temperatures and carbon-dioxide conditions.  This would also reduce some of 
the confounding variables of taking tissue plugs from the in vivo study and 
exposing to the neuronal cultures, as described above, such as apoptosis 
(cellular debris), toxic molecules such as nitric oxide and other reactive oxygen 
species, endogenous VEGF and GDNF, the activation of other cell types 
(microglia, oligodendrocytes, astrocytes, Schwann cells) by VEGF and GDNF.  
A more complex, and possibly more effective combinational treatment 
approach would be to embed cells (Schwann cells, neural progenitor cells, 
oligodendrocyte progenitors, endothelial cells) into the hydrogel matrix and then 
mix trophic factors (encapsulated within nanospheres or without encapsulation) 
into the hydrogel.  Dr. Mary Bunge has been investigating the beneficial effects of 
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Schwann cells (SCs) for the repair of tissue following SCI, and in combinational 
treatment approaches for the past ~40 years, work started by Dr. Richard Bunge 
in 1975 (Bunge MB, 2016).  In a more recent study, Williams and Bunge (2015) 
detail the positive effects of SCs on promoting axonal regeneration, myelination 
of regenerated axons, reducing cystic cavitation and secondary injury, as well 
some functional improvement. Combining SC therapy with other neurotrophic 
factors, enzymes, cells, and other treatments, for a combinational approach 
enhances the functional recovery and results in greater axonal regrowth 
(Williams and Bunge, 2015).  This work, among Dr. Bunge’s enormous expanse 
of SCI and SC literature, once again nicely highlights the importance of 
combinational approaches for the treatment of SCI.  Another study conducted by 
this group used a bioengineered bridge to support and encourage the extension 
of axons, astrocytes, and Schwann cells across the matrigel bridge and beyond 
the distal end of the lesion site.  Brainstem axons regenerated across the 
matrigel bridge and formed functional connections onto dendrites in the caudal 
host tissue following a T8 complete transection injury.  Improvement in hindlimb 
motor function directly correlated with the number of brainstem regenerated 
axons and GFAP positive astrocytic fibers which entered the matrigel bridge 
along with the transplanted SCs (Williams et al., 2015).  This study also 
demonstrates the importance of combinational treatment approaches. 
 Schwann cells are currently the only FDA (Food and Drug Administration) 
approved cell type for human clinical spinal cord injury studies (Xu XM, 2012; 
Guest et al., 2013).  While transplanted cells can be genetically engineered to 
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overexpress VEGF or GDNF, studies in which cells are embedded within the 
hydrogel containing trophic factors have a much greater propensity for safety as 
far as clinical trials, due to the fact that the trophic factors will ultimately be 
biodegraded over time, as will the hydrogel.  Transplanting hydrogel containing 
cells that are genetically modified to overexpress certain trophic factors holds the 
concern of long-term cell survival, even after hydrogel biodegradation, and thus 
long-term synthesis and release of growth factors which could result in 
unregulated cell growth or tumor formation; which is always a major concern with 
administering trophic factors with no terminal time point of synthesis or release. 
Additionally, enzymes could also be mixed within the hydrogel in addition 
to cells and trophic factors, such as Chondroitinase ABC (ChABC; Houle et al., 
2006), which helps to degrade the inhibitory components of the glial scar, namely 
the chondroitin sulfate proteoglycans (Nogo-A, aggrecan, keratin, brevican, 
neurocan, phosphocan).  Due to ChABC’s enzymatic nature, it can be degraded 
quickly by the surrounding tissues.  Thus, embedding ChABC into hydrogel or 
into nanospheres within the hydrogel will not only afford tighter control over its 
release profile at the site of injury, but will also protect the enzyme from being 
quickly degraded.  Hydrogel containing ChABC (embedded in nanospheres; 
Houle et al., 2006), VEGF (in nanoparticles), GDNF (in different nanoparticles; 
Dolbeare and Houle, 2003; Deng et al., 2013), and endothelial cells and neural 
progenitor cells (Rauch et al. 2009), for example, might be a powerful 
combinational treatment approach, based on previous SCI literature with each of 
these individual treatment approaches, and some combinational therapies. 
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Combinational Treatment Approaches Employed for SCI 
In a combinational treatment approach, Rauch et al. (2009) transplanted a 
co-culture of endothelial cells and neural progenitor cells embedded within a 
PLGA biodegradable polymer following a hemisection SCI.  Compared to SCI 
lesion or PLGA alone, the PLGA plus endothelial cells as well as the PLGA plus 
neural stem cells both promoted twice the number of angiogenic vessels.  
Furthermore, the combination of PLGA with endothelial cells and neural 
progenitor cells resulted in twice as much vasculature as PLGA with either cell 
type alone.  Only the treatment group containing both endothelial cells and neural 
progenitor cells showed the formation of a blood-spinal cord barrier, highlighting 
the beneficial effects of the multiple cell type combinational treatment approach. 
In 2006, significant axonal growth of the corticospinal and raphespinal 
tracts was observed following thoracic SCI, in response to a combinational 
therapy comprised of a photoactivated hydrogel embedded with NT3 (Piantino 
et al.).  This study is significant considering the difficulty of promoting outgrowth 
from descending corticospinal tracts.  Additionally, this study also observed 
significant improvement in functional recovery, which is also not trivial to 
achieve with a complete transection injury model (T8). 
In addition to combinational treatment approaches appearing to hold the 
greatest therapeutic potential for SCI, the current study emphasized the 
importance of combining multiple locomotor assessments and measures of 
functional recovery.  When observing grooming behavior during the BBB and 
Hargreaves’ tests, it was apparent that some of the rats could support their entire 
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body weight on their hindlimbs and groom with both forepaws simultaneously, 
similar to sham animals.  However, some rats could not fully support their body 
weight on their hindlimbs, thus it was necessary for them to prop themselves up 
on one forepaw while grooming with the other forepaw, and then switch their 
body weight to the other forepaw to be able to groom with the second forepaw.  
Therefore, the grooming test was modified for use as a functional measure of 
trunk stability.  The trends observed were not statistically significant, although it 
appears that this might be a useful measurement for thoracic SCI, in conjunction 
with the BBB, TreadscanTM or CatwalkTM, and Gridwalk.  The Grooming test 
requires no animal training and can be observed within a number of 
environments, including the animal’s home cage, the BBB open field, and the 
Hargreaves’ testing environment.  Rodents are compulsive groomers and stop to 
groom frequently once they are comfortable in their surrounding environment. 
Therapies targeting the vasculature appear to be promising and necessary 
for minimizing tissue ischemia, reducing tissue toxicity, and promoting tissue 
repair.   Intact vasculature is crucial for delivering oxygen and nutrients to the 
tissue, and for removing cellular wastes.  In a combinational therapy approach, 
Han et al. (2010) administered angiopoietin-1 and alpha v beta 3 integrin (factors 
known to promote endothelial cell survival), after contusive, thoracic SCI.  This 
treatment strategy resulted in spared lesion vasculature, increased white matter 
sparing, decreased inflammatory response, and improved locomotion; thus, 
emphasizing the importance of the vasculature in the secondary wave of injury 
caused by the inflammatory response (Han et al., 2010). 
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Popovich and colleagues illustrated the high potential of vascular 
plasticity, up to 28 days following SCI (1996).  Benton et al. (2008a) used a novel 
technique for identifying vasculature, and determined that a specific subclass of 
spinal microvasculature (within the lesion core), demonstrates tight junction 
dysfunction.  Later in 2008, Benton and colleagues published another report 
detailing the microvascular dysfunction and identification of a number of 
upregulated mRNAs as early as 24 hours post SCI (Benton et al., 2008b).   
Collectively, the studies highlighted in this dissertation demonstrate the 
importance of combinational treatment approaches (Bunge MB, 2008), 
combinations of functional assessments to measure deficits and recovery 
following SCI, the usefulness of bioengineered tissues as therapies, and the 
positive impact on tissue repair with VEGF and GDNF for SCI repair.  
Furthermore, we and others have highlighted the fact that VEGF might have a 
positive effect in vivo, primarily when combined with other factors, such as GDNF 
or PDGF.  Additionally, the background literature demonstrates that the 
combination of VEGF and GDNF has broader implications for targeting the 
vasculature and for neuroprotection beyond SCI, for other neurodegenerative 
diseases (Alzheimer’s disease, Huntington’s disease, Amyotrophic Lateral 
Sclerosis, and stroke). 
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2000 – 2003 Laboratory Assistant • Dr. Arthur W. Toga LONI • 
Department of Neurosurgery, University of California at 
Los Angeles (UCLA), Los Angeles, California 
2000 – 2001 Laboratory Assistant • Dr. John Merriam • Molecular Cell 
& Developmental Biology Department University of 
California at Los Angeles (UCLA) • Los Angeles, 
California 
1990 – 2000 Clerical Staff • Gary Walker & Associates • Consulting 
Engineers • Simi Valley, California 
 
Grants & Fellowships 
 
2014 – 2015 Individual Research Grant, Wings for Life Spinal Cord Injury 
Research Foundation • Grant renewed in 2014 
 
2013 – 2014 Individual Research Grant, Wings for Life Spinal Cord Injury 
Research Foundation, *One of only ten total Individual 
Research grants funded worldwide in 2013 
 
2009 – 2010 T32 • Predoctoral NIAAA Training Fellowship • Indiana 
Alcohol Research Center 
 Teaching Experience 
 
2000 Undergraduate Teaching Assistant • Life Science 4 • Genetics 
 University of California at Los Angeles (UCLA), Los Angeles, 
 California  
 
Professional Societies & Affiliations 
 
2015-present Journal of Spine, Neurology & Neurophysiology, Editorial 
Board 
2008-present IndyHub Young Professionals’ Organization 
2002-present International Society for the History of Neurosciences 
2012-present International Society for Neuroscience 
2011-2012 National Neurotrauma Society 
2011-2012 Women in Neurotrauma 
2011-2012 North American Vascular Biology Organization 
2011-2012 Sigma Xi, The Scientific Research Society           
2011-2012 American Association for the Advancement of Science  
 
Honors & Awards         
  
2015 Graduate Student Travel Fellowship Award • Indiana University 
Purdue University Indianapolis 
2014 Science Photo Contest • International Society for Neuroscience 
2012 Outstanding Oral Presentation • International Neural 
Regeneration Symposium, Shenyang, China 
2012 IBMG Graduate Student Ambassador Volunteer Appreciation • 
Indiana University School of Medicine 
2011 First Place in Poster Competition • Indianapolis Society for 
Neuroscience 
2011 Honorary Mention • Sigma Xi Research Competition • Indiana 
University School of Medicine 
2010 Educational Enhancement Grant • Indiana University Graduate 
Student Organization 
2000 Undergraduate Teaching Assistantship • Life Science 4 • 
Genetics • UCLA 
1999 Honor’s Content • Life Science 4 • Genetics • UCLA 
1996-1998 California Dean’s Honor List • 3 Semesters • Moorpark 
Community College 
1996 Middleton Scholarship • Royal High School • Simi Valley • 
California 
1995 California Girls State • Royal High School Representative • 
American Legion Auxiliary 
Mentoring Experience 
 
Student Mentor 
 
2012-2013 IBMG Graduate Student • IUSM • Indianapolis 
2012-2013 IBMG Graduate Student • IUSM • Indianapolis 
2013-2013 IBMG Graduate Student • IUSM • Indianapolis 
2011-2012 IBMG Graduate Student • IUSM • Indianapolis 
2011  Post baccalaureate Student • IUSM • Indianapolis 
2011 IBMG Graduate Student • IUSM • Indianapolis 
2010-2011 IBMG Graduate Student • IUSM • Indianapolis 
2010-2011 IBMG Graduate Student • IUSM • Indianapolis 
2009-2010 IBMG Graduate Student • IUSM • Indianapolis 
2008-2009 IBMG Incoming Student • IUSM • Indianapolis 
2008-2009 IBMG Graduate Student • IUSM • Indianapolis 
 
Research Mentor 
 
2015 Undergraduate Intern • Earlham College • Richmond Indiana • 
Xu Laboratory 
2015 Post baccalaureate Student Rotation • IUSM • Indianapolis • 
 Xu Laboratory 
2011-2015 Post baccalaureate Student • IUSM • Indianapolis • 
 Xu Laboratory 
2015 Post baccalaureate Student Rotation • IUSM • Indianapolis • 
 Xu Laboratory 
2013 Undergraduate Student • IUPUI • Indianapolis • Xu Laboratory 
2013 Master’s Student • IUPUI • Indianapolis • Xu Laboratory 
2012 Medical Student • IUSM • Indianapolis • Xu Laboratory 
2011 Undergraduate Student • Mount Holyoke College • 
Massachusetts • Xu Laboratory 
 
Student Ambassador        
  
2009-2012 Annual IUSM IBMG Student Ambassador 
2008-2010 Annual Tokyo Student Ambassador 
2008-2009 Student Ambassador, International English Language School 
Students 
 
 
 
 
Skills & Training Experience        
 
2010-2016 Spinal cord injury (SCI) and repair dissertation research 
utilizing novel Bioengineered Hydrogel 
• Earned international research grant: Wings for Life (2013 
and 2014) • only 10 grants awarded globally in 2013 
• Eleven formal seminar presentations 
 
2007-2010 Clinical Alcohol Addiction Research (fMRI and PET 
Neuroimaging) 
• Proposed/designed a macro with a programmer and 
reduced 6 weeks of analysis down to 4 minutes. 
• Set up software/device for misting alcohol • established 
the idea of using Gatorade® (control drink) for fMRI 
 
2004  Oncology Research/Cancer therapeutics (lymphoma and 
leukemia, monoclonal antibodies) 
• Biomedical research training: Immunohistochemistry • 
Cell/Bacterial Cultures • Mice Tail-vein injections • Flow 
cytometry • Protein purification • cryopreservation • brain 
slicing/dissection • human autopsy 
 
2000-2003 Clinical and Rodent Functional Neuroimaging 
• Discovered/resolved vascular dilation problems resulting 
from inhalational anesthetics. 
• Clinical imaging:  Intraoperative optical intrinsic signal 
imaging (iOIS) and near-infrared spectroscopy (NIRS) 
during human neurological surgeries (identification of 
eloquent language, sensory, and motor cortices) 
• Biomedical training: Neuroimaging, Anatomy, 
Anesthesiology, Surgical Techniques, Physiology 
 
2000-2001 Molecular Cell & Developmental Biology    
• Designed and created unique study section on 
Bacteriophage viruses for university students nationwide 
• Learned Authorware computer program 
 
1990-2000 Part-time Clerical Staff     
• Learned Microsoft Word and Excel programs 
• Established electronic bank and credit card statement 
reconciliation system; figured bi-weekly payroll and taxes 
• Coordinated: meetings, job-site walk-throughs, trips 
• Typed letters/meeting minutes 
• Filed job reports and assisted with Job-site walk-throughs 
Publications          
   
Book   
 
2008 Gloria Walker, Melissa Walker, Ryan Lanigan (Illustrator).  “Stop & 
Go Safety.” • Children’s book • Publisher: The Clark Group 
 
Articles 
 
1. Lin X.J., Zhao T., Walker M.J., Ding A. Jiang M., Cao J. Lin S., Xu 
X.M., Liu S. “Pro-oligodendroblasts, activated by M1 microglia, 
promote functional recovery after acute contusive spinal cord injury.” 
Cell Transplantation (Accepted). 
 
2. Walker CL, Zhang YP, Liu Y, Li Y, Walker MJ, Liu NK, Shields CB, Xu 
XM. “Anatomical and Functional Effects of Lateral Cervical 
Hemicontusion in Adult Rats”. Restorative Neurology and 
Neuroscience (Accepted). 
 
3. Wang H, Liu NK, Zhang YP, Deng L, Lu QB, Shields CB, Walker MJ, 
Li J, Xu XM. “Treadmill training induced lumbar motoneuron dendritic 
plasticity and behavior recovery in adult rats after a thoracic contusive 
spinal cord injury.” Experimental Neurology, 2015 September (doi: 
10.1016/j.expneurol.2015.07.004). 
 
4. Ma Z, Zhang YP, Liu W, Yan G, Li Y, Shields LBE, Walker MJ, Chen 
K, Huang W, Kong M, Lu Y, Brommer B, Chen X, Xu XM, Shields CB. 
“A controlled spinal cord contusion for the rhesus macaque monkey.” 
Experimental Neurology, 2016 February 11 (doi: 
10.1016/j.expneurol.2016.02.008). 
 
5. Melissa J. Walker‡, Chandler L. Walker‡, Y. Ping Zhang, Lisa B. E. 
Shields, Christopher B. Shields, and Xiao-Ming Xu. “A Novel Vertebral 
Stabilization Method for Producing Contusive Spinal Cord Injury.” 
Journal of Visualized Experiments (JoVE), 2015 Jan 5;(95):e50149. 
doi: 10.3791/50149. ‡Co-first authors. 
 
6. Yi Ping Zhang, Melissa J. Walker , Lisa B. E. Shields, Xiaofei Wang, 
Chandler L.Walker, Xiao-Ming Xu, Christopher B. Shields. “Controlled 
Cervical Laceration Injury in Mice.” Journal of Visualized Experiments 
(JoVE). 2013 May 9;(75):e50030. doi: 10.3791/50030. 
 
7. Walker CL, Walker MJ, Liu N-K, Risberg EC, Gao X, Chen J, Xu X-M. 
“Systemic bisperoxovanadium activates Akt/mTOR, reduces 
autophagy, and enhances recovery following cervical spinal cord 
injury.” PLoS One. 2012  7(1):e30012. 
8. Kareken DA, Grahame N, Dzemidzic M, Walker MJ, Lehigh CA, 
O’Connor SJ.  “fMRI of the Brain’s Response to Stimuli Experimentally 
Paired with Alcohol Intoxication.” Psychopharmacology.  2012 Apr; 
22(4): 787-97. 
 
9. Sheth S, Nemoto M, Guiou M, Walker M and Toga AW.  
"Spatiotemporal evolution of functional hemodynamic changes and 
their relationship to neuronal activity." J Cereb Blood Flow Metab. 2005 
Jul; 25(7): 830-41. 
 
10. Guiou M, Sheth S, Nemoto M, Walker M, Pouratian N, Ba A and Toga 
AW. "Cortical spreading depression produces long- term depression of 
activity-related changes in cerebral blood volume and neurovascular 
coupling."J Biomed Opt. 2005 Jan-Feb; 10(1): 11004. 
 
11. Sheth SA, Nemoto M, Guiou M, Walker M, Pouratian N, and Toga AW. 
"Linear and nonlinear relationships between neuronal activity, oxygen 
metabolism, and hemodynamic responses." Neuron 2004 Apr 22; 
42(2): 347-55. Cover article. 
 
12. Sheth SA, Nemoto M, Guiou M, Walker M, Pouratian N, Hageman N, 
and Toga AW. "Columnar specificity of microvascular oxygenation and 
volume responses: implications for functional brain mapping." J 
Neurosci. 2004 Jan 21; 24(3): 634-41. 
 
13. Sheth S, Nemoto M, Guiou M, Walker M, Pouratian N and Toga AW. 
“Evaluation of coupling between optical intrinsic signals and neuronal 
activity in rat somatosensory cortex.” NeuroImage 2003 Jul; 19(3): 884-
94. 
 
Selected Abstracts         
  
1. Lin X., Zhao T.B., Walker M., Wu W., Xu X.M.  Assessing motor 
deficits in a rodent model of spinal cord hemisection that mimics the 
human Brown-Sequard syndrome. 46th International Meeting of the 
Society for Neuroscience, San Diego, CA, to be held November 2016. 
 
2. Lin X., Xiong W., Wu W., Walker MJ., Jin X., Xu X.M.  Imaging neural 
activity in the primary somatosensory cortex using GCaMP transgenic 
mice. 46th International Meeting of the Society for Neuroscience, San 
Diego, CA, to be held November 2016.*Dynamic poster. 
 
3. Lin X., Zhao T., Xiang G., Xiong W., Zhao S., Wu W., Walker M., Ping 
X., Lin S., Jin X., Chen J., Gan W., Xu X.M.  Dendritic plasticity of layer 
V pyramidal neurons in the primary motor cortex after lesions to the 
pyramid and thoracic spinal cord. 45th International Meeting of the 
Society for Neuroscience, Chicago, IL, October 19, 2015. 
4. Lin X., Zhao T., Walker M., Ding A., Jiang M., Cao J., Lin S., Xu X.M., 
Liu S.  Transplantation of pro-oligodendroblasts, preconditioned by 
LPS-stimulated microglia, promotes recovery after acute contusive 
spinal cord injury. 45th International Meeting of the Society for 
Neuroscience, Chicago, IL, October 17, 2015. 
 
5. Deng L., Sun Y., Ruan Y., Walker M., Hamilton M., Qu W., Wang Y., 
Smith G.M., Xu X.M.  Functional regeneration of descending 
propriospinal axons through and beyond a growth-promoting pathway 
constructed by transplanted Schwann cells overexpressing GDNF after 
a thoracic spinal cord transection in adult rats. 45th International 
Meeting of the Society for Neuroscience, Chicago, IL, October 18, 
2015. 
 
6. Lin X., Zhao T., Xiong W., Walker M., Lin S., Walker C., Jin X., Xu 
X.M., Liu S.  Intercostal nerve-lumbar dorsal root anastomosis 
promotes axonal regeneration beyond a spinal cord injury.  21st Annual 
Kentucky Spinal Cord Head Injury Research Trust Symposium, 
Louisville, KY, May 20-21, 2015. (Presented). 
 
7. Colin M.E. Fry, Chandler L. Walker, Nai-Kui Liu, Alex Giannaris,  
Mathew Hamilton, Melissa J. Walker, Qingbo Lu,  Xiao-Ming Xu.  A 
gender comparison for moderate thoracic midline spinal cord contusion 
injury in adult rats. 21st Annual Kentucky Spinal Cord Head Injury 
Research Trust Symposium, Louisville, KY, May 20-21, 2015. 
 
8. Lin X., Zhao T., Xiong W., Walker M., Lin S., Walker C., Jin X., Xu 
X.M., Liu S.  Intercostal nerve-lumbar dorsal root anastomosis 
promotes axonal regeneration beyond a spinal cord injury. 44th 
International Meeting of the Society for Neuroscience, Washington, 
DC, November 18, 2014. Hot Topics. 
 
9. Melissa J. Walker, Lingxiao Deng, Chandler L. Walker, Wenjie Wu, 
Xiangbing Wu, Qingbo Lu, Sarah M. Wilson, Rajesh Khanna, Naikui 
Liu, Xuejun Wen, Ning Zhang, and Xiao-Ming Xu. Novel Bioengineered 
Hydrogel Combinational Therapy for Traumatic Spinal Cord Injury. 6th 
Annual Wings for Life Annual Meeting, Salzburg, Austria, May 21-22, 
2014. 
 
10. Chandler L. Walker, Xiaofei Wang, Carli L. Bullis, Colin Frye, Melissa 
J. Walker, Lingxiao Deng, Qingbo Lu, Xiao-Ming Xu.  Benefits of a 
novel combination acute bisperoxovanadium and subacute Schwann 
cell transplantation therapy following spinal cord injury. 43rd 
International Meeting of the Society for Neuroscience, San Diego, CA, 
November 10, 2013. 
 
11. Melissa J. Walker, Wenjie Wu, Lingxiao Deng, Jian Zou, Chandler L. 
Walker, Qingbo Lu, Naikui Liu, Xuejun Wen, Ning Zhang, and Xiao-
Ming Xu.  Improved Functional Recovery after Contusive Spinal Cord 
Injury following Transplantation of a Novel Bioengineered Hydrogel 
containing GDNF and BDNF. 19th Annual Kentucky Spinal Cord Head 
Injury Research Trust Symposium, Louisville, KY, May 6-7, 2013. 
 
12. Melissa J. Walker‡, Wenjie Wu‡, Lingxiao Deng, Jian Zou, Chandler L. 
Walker, Qingbo Lu, Naikui Liu, Xuejun Wen, Ning Zhang, and Xiao-
Ming Xu.  Novel Bioengineered Hydrogel Combined with BDNF and 
GDNF Improves Functional Recovery following Traumatic Contusive 
Spinal Cord Injury. 2nd International Neural Regeneration Symposium, 
Shenyang, China, September 21-23, 2012.  ‡Co-first authors. 
 
13. Melissa J. Walker, Wenjie Wu, Lingxiao Deng, Jian Zou, Chandler L. 
Walker, Naikui Liu, Xuejun Wen, Ning Zhang, Xiao-Ming Xu.  
Combinational treatment of transplanted bioengineered hydrogel 
containing GDNF and BDNF promotes improved functional recovery 
following contusive spinal cord injury. 42nd International Meeting of the 
Society for Neuroscience, New Orleans, LA, October 13-17, 2012. 
 
14. Walker Melissa J, Walker Chandler L, Xu Xiao-Ming.  Development of 
a Novel Forelimb Assessment of Skilled Coordinated Object 
Manipulation following Cervical Spinal Cord Injury. Indianapolis Society 
for Neuroscience Symposium, Indianapolis, IN, October 7, 2011. (First 
Place in Poster Competition) 
 
15. Chandler L. Walker, Melissa J. Walker, Nai-Kui Liu, and Xiao-Ming 
Xu.  Bisperoxovanadium-mediated neuroprotection, functional 
recovery, and PI3K-Akt-mTOR activity following cervical contusive 
spinal cord injury. 41st International Meeting of the Society for 
Neuroscience, Washington, DC, November 12-16, 2011. 
 
16. Walker Chandler L, Walker Melissa J, Xu Xiao-Ming.  Acute 
Bisperoxovanadium Therapy Stimulates Akt and mTOR Activity, 
Reduces Autophagy, and Promotes Neuroprotection and Functional 
Recovery following Cervical Contusive Spinal Cord Injury. National 
Neurotrauma Symposium, Fort Lauderdale, Florida, July 10-13, 2011. 
(Poster Finalist) 
 
17. Kareken DA, Walker MJ, Cox CA, Dzemidzic M, Windisch, Grahame 
NJ, O’Connor SJ.  Regional Brain Responses to Experimentally 
Classically Conditioned Novel Cues of Alcohol Intoxication, 
International Society for Biomedical Research on Alcoholism, Paris, 
France, September 13, 2010. 
 
18. Kareken DA, Walker MJ, Dzemidzic M, Bragulat V, Oberlin BG, 
Albrecht DS, Yoder KK.  Human ventral striatal dopamine receptor 
availability as a function of alcoholic drink tastes, International Society 
for Biomedical Research on Alcoholism, Paris, France, September 13, 
2010. 
 
19. Walker M, Cox C, Bragulat V, Dzemidzic M, Windisch K, O’Connor SJ, 
Grahame NJ, Kareken DA.  Negative Prediction Error to Classically 
Conditioned Novel Cues of Alcohol Intoxication, 33rd Annual Research 
Society on Alcoholism, San Antonio, TX, June 26, 2010. 
 
20. Walker M, Bragulat V, Dzemidzic M, Cox C, Talavage T, Davidson D, 
O’Connor SJ, Kareken DA.  Family History of Alcoholism and Smoking 
as Mediators of the Brain’s Response to Alcohol’s Olfactory Cues, 3rd 
Annual Integrated Biomedical Gateway Recruitment Poster Session, 
Indiana University School of Medicine, Indianapolis, IN, February 19, 
2009. 
 
21. Sheth S, Guiou M, Nemoto M, Walker M & Toga AW.  Linear and 
nonlinear relationships between neuronal activity, oxygen metabolism, 
and hemodynamic responses, 34th International Meeting of the Society 
for Neuroscience, San Diego, CA, October 23-27, 2004. 
 
22. Sheth S, Hageman N, Guiou M, Walker M, Nemoto M, Pouratian N & 
Toga AW 2003 Advantages of Functional Brain Mapping Using 
Cerebral Blood Volume Contrast, 9th Annual Meeting of the 
Organization for Human Brain Mapping, New York City, NY, June 18-
22, 2003. 
 
23. Sheth S, Guiou M, Nemoto M, Hageman N, Walker M & Toga AW 
2003 Coupling Between Cerebral Blood Volume and Cerebral Blood 
Flow in Rat Somatosensory Cortex, 9th Annual Meeting of the 
Organization for Human Brain Mapping, New York City, June 18-22, 
2003. 
 
24. Hageman N, Sheth S, Guiou M, Nemoto M, Walker M & Toga AW 
2003 Basal Conditions Affect Cerebral Perfusion in the Rat 
Somatosensory Cortex, 9th Annual Meeting of the Organization for 
Human Brain Mapping, New York City, June 18-22, 2003. 
 
25. Sheth S, Hageman N, Guiou M, Walker M, Nemoto M, Pouratian N & 
Toga AW 2003 Advantages of Functional Brain Mapping Using 
Cerebral Blood Volume Contrast, 21st International Symposium on 
Cerebral Blood Flow, Metabolism, and Function, Calgary, Canada, 
June 29-July 3, 2003. 
 
26. Hageman N, Sheth S, Guiou M, Nemoto M, Walker M & Toga AW 
2003 Coupling between cerebral blood volume and cerebral blood flow 
in rat somatosensory cortex, 21st International Symposium on Cerebral 
Blood Flow, Metabolism, and Function, Calgary, Canada, June 29-July 
3, 2003.  
 
27. Guiou M, Sheth S, Nemoto M, Walker M, Pouratian N & Toga AW.  
Neurovascular uncoupling and suppression of intrinsic cerebrovascular 
motion by cortical spreading depression, 33rd International Meeting of 
the Society for Neuroscience, New Orleans, LA, November 8-12, 2003. 
 
28. Sheth S, Nemoto M, Guiou M, Walker M, Pouratian N and Toga AW.  
Spatial specificity of functional brain mapping signals is a function of 
timing more than etiology, 33rd International Meeting of the Society for 
Neuroscience, New Orleans, LA, November 8-13, 2003. 
 
29. Sheth S, Guiou M, Nemoto M, Walker M, Pouratian N and Toga AW.  
Optical intrinsic signal and laser Doppler imaging in rat somatosensory 
cortex, 32nd International Meeting of the Society for Neuroscience, 
Orlando, FL, November 2-7, 2002. 
 
30. Guiou M, Sheth S, Nemoto M, Walker M, Pouratian N, Ba A, Chen J 
and Toga AW.  Cortical spreading depression produces long-term 
disruption of activity-related changes in cerebral blood flow and 
volume, 32nd International Meeting of the Society for Neuroscience, 
Orlando, FL, November 2-7, 2002. 
 
31. Sheth S, Nemoto M, Walker M, Guiou M and Toga AW.  Hemoglobin 
concentration mapping using two-dimensional spectrophotometry, 8th 
Annual Meeting of the Organization for Human Brain Mapping, Sendai, 
Japan, June 2-6, 2002. 
 
32. Sheth S, Nemoto M, Guiou M, Walker M, Lee S and Toga AW.  
Combined optical intrinsic signal and laser Doppler imaging in rodent 
somatosensory cortex, 8th Annual Meeting of the Organization for 
Human Brain Mapping, Sendai, Japan, June 2-6, 2002. 
 
33. Guiou M, Sheth S, Nemoto M, Walker M, Ba A, Pouratian N, Chen J 
and Toga AW.  Cortical spreading depression produces long-term 
attenuation and uncoupling of activity-related optical intrinsic signals to 
neuronal activity, 8th Annual Meeting of the Organization for Human 
Brain Mapping, Sendai, Japan, June 2-6, 2002. 
 
 
 
Conferences 
 
2015 Kentucky Spinal Cord Head Injury Research Trust Symposium 
(Poster Presentation), 21st Annual Meeting, Louisville, Kentucky 
 
2015 Wings for Life Annual Meeting (Oral Presentation) 
 7th Annual Meeting, Salzburg, Austria  
 
2015 Neuroscience Innovation Day, (Poster Presentation) 
 1st Annual, Indianapolis, Indiana, IUSM, IU Health, Purdue 
Engineering 
 
2014 International Meeting of the Society for Neuroscience (Attended) 
 44th International Meeting, Washington, DC 
 
2014 Indianapolis Society for Neuroscience (Attended) 
 Annual Meeting, Indianapolis, Indiana 
 
2014 Wings for Life Annual Meeting (Poster and Oral Presentation) 
 6th Annual Meeting, Salzburg, Austria 
 
2013 Indianapolis Society for Neuroscience (Attended) 
 Annual Meeting, Indianapolis, Indiana 
 
2013 Kentucky Spinal Cord Head Injury Research Trust Symposium 
(Poster Presentation), 19th Annual Meeting, Louisville, Kentucky 
 
2012 International Meeting of the Society for Neuroscience (Poster 
Presentation), 42nd International Meeting, New Orleans, Louisiana 
 
2012 Linda and Jack Gill Symposium (Poster Presentations, 2 posters) 
 7th Annual Symposium, Bloomington, Indiana 
 
2012 International Neural Regeneration Symposium (2 Posters and Oral 
Presentation), 2nd Annual Meeting, Shenyang, China   (Outstanding 
Oral Presentation) 
 
2012 Indiana Spinal Cord and Brain Injury Research Conference 
(Attended) 
 2nd Annual Meeting, Indianapolis, Indiana 
 
 
2012 Kentucky Spinal Cord Head Injury Research Trust Symposium 
(Attended), 18th Annual Meeting, Lexington, Kentucky 
 
2011 North American Vascular Biology Organization (Attended) 
 Vascular Matrix Biology and Bioengineering Annual Meeting, Hyannis, 
Massachusetts 
 
2011 National Neurotrauma Society (Poster Presentation) 
 Annual Meeting, Fort Lauderdale, Florida 
 
2011 Indianapolis Society for Neuroscience (1st Place – Poster 
Competition),  Annual Meeting, Indianapolis, Indiana 
 
2011 Kentucky Spinal Cord Head Injury Research Trust Symposium 
(Poster Presentation), 17th Annual Meeting, Louisville, Kentucky 
 
2010 Indianapolis Society for Neuroscience (Attended) 
 Annual Meeting, Indianapolis, Indiana 
 
2010 Linda and Jack Gill Symposium (Poster Presentation) 
 5th Annual Symposium, Bloomington, Indiana 
 
2010 Research Society on Alcoholism (Poster Presentation) 
 33rd Annual National Meeting, San Antonio, Texas 
 
2009 Indianapolis Society for Neuroscience (Poster Presentation) 
 Annual Meeting, Indianapolis, Indiana 
 
2008 Indianapolis Society for Neuroscience (Attended) 
 Annual Meeting, Indianapolis, Indiana 
 
2008 Research Society on Alcoholism (Attended) 
 31st Annual National Meeting, Washington DC 
 
2008 Indiana Neuroimaging Symposium (Attended) 
 2nd Annual Meeting, Indianapolis, Indiana 
 
2008 Indiana Symposia on Mild Cognitive Impairment (Attended) 
 2nd Annual Meeting, Indianapolis, Indiana 
 
 
 
2007 Indianapolis Society for Neuroscience (Attended) 
 Annual Meeting, Indianapolis, Indiana 
 
2007 Adult Skeletal Muscle Symposium: Growth, Function and 
Mobility, Eli Lilly (Attended), Indianapolis, Indiana 
 
2002 International Meeting of the Society for Neuroscience (Co-
presented two posters), 32nd International Meeting, Orlando, Florida 
 
2002 International Society for the History of Neurosciences (Attended) 
 7th Annual Meeting, Los Angeles, California 
 
